Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/cat_index.php on line 1

Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/cat_index.php on line 1

Warning: main() [function.include]: Failed opening '/home/corante/public_html/pipeline/includes/header.html' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/corante/public_html/pipeline/archives/cat_index.php on line 1
About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night

In the Pipeline

Category Index
"Me Too" Drugs
Translation Needed
Those Me-Too Drugs
Biosimilars: Not So Dang Easy
Pfizer's Future: Biotech Followups
Arzoxifene: Not the Road to Big Profits?
Now Your Liver Doesn't Have to Make It For You
How Many PPIs Does the World Need?
Bad Luck For Novartis - And For Diabetics
Godzilla vs. Mothra? Relman vs. Epstein!
By a Nose in a Head to Head
No Clear Winners
Gritting Our Teeth
An Economist Who Gets It
Alex Tabarrok on Me-Too Drugs
Blurry Copies
The Last Word (For A While) On Me-Too Drugs
Me Too, Part Two
Clinical Trials And What to Do With Them
Hypertension and Marketing
Merck and Its Competition
Our Buddies at the FDA
Adam Smith Goes Pharmaceutical
Innovation and Its Discontents
Claritin and Clarinex

Academia (vs. Industry)
Academia and Industry, Suing Each Other
Panel on Academic-Industrial Collaboration in Drug Discovery
Francis Collins Speaks
Does Anyone Want the NIH's Drug Screening Program?
"The Smarter You Are, The More I Will Hate You"
Publishing, Perishing, Buying and Selling
How Many New Drug Targets Aren't Even Real?
Broader Impacts Indeed
The NIH and Conflicts of Interest
What Translational Research Should Academia Do?
Academic Drug Discovery: A Survey
Roche Prevails Over Stanford
Maybe It Really Is That Hard?
Translation Needed
The PhD Problem: A Global Perspective
Nothing Personal
Roche and Stanford: Academia v. Industry?
What If Those Wonderful Results Are Wrong?
The NIH Goes For the Gusto
More On the Postdoc Situation
A Postdoc's Lament
Gonna Focus on Re-Engineering the Tools for the Process
New Cures! Faster! Faster!
The NIH's New Drug Discovery Center: Heading Into the Swamp?
Friday Mental Health Break: "Bad Project"
Chemistry Jobs Roundtable: What About Tenure?
Design Your Own Lab Course
And One Was Just Right?
Where Drugs Come From: By Country
Where Drugs Come From: The Numbers
Another Set of Eyes
A Pile of Malaria Leads For the Taking
Reasons Not to Go to Grad School?
All Of You Industrial Scientists: Out Of the Room
Fear Of Academic Chemistry?
Short Topics From All Over
I'll See Your Conflicts, and Raise You?
The Grant Application Treadmill
Industrial Research: More Grounded in Reality, or Not?
To What End?
Just Give It to NIH
Wasted Money, Wasted Time?
Where Drugs Come From, and How. Once More, With A Roll of the Eyes
More Hot Air From Me on Screening
Competing (And Competing Unethically?)
Poor Equipment Revisited
The Perils of Poor Equipment
More Than This
Lowe's Law of Diurnal Distribution
Getting To Lyrica
Scrape Off Some Attitude
Ugly, But Useful
Drugs From Where?
The Doctorate and Its Discontents
Naked Synthesis
What Can Academia Do?
Problems and Solutions
Peter Kim, So Far
Not On the Same Page
University of Drug Discovery?
The Great Divide
Mutual Suspicions
Differences Between Academia and Industry, Pt. 4
Sneaking Out for an Interview
Getting A Job
More on Question Four
Getting a Faster PhD?
The Bones of the World
Don't Become A Scientist?
Like Moving Furniture Across a Tightrope
Gumming Up the Amyloid Works
The NIH in the Clinic
One More On Basic Research and the Clinic
A Real-World Can O' Worms
How Much Basic Research?
How It Really Works
Will the Uncommon Work for the Common Good?
Industry vs. Academia: The Mental Aspect
Stuart Schreiber on Stuart Schreiber
Differences Between Academia and Industry, Pt. 2
Differences Between Industry and Academia, Pt. 1
On the Money

Aging and Lifespan
Defending Das' Resvertrol Research. Oh, Come On.
A Resveratrol Research Scandal. Oh, Joy.
The Sirtuin Saga
Resveratrol in Humans: Results of a Controlled Trial
The Latest Sirtuin Controversy
Big Sirtuin News
SRT1720: Good (And Confusing) News for Obese Mice
mINDY Mice - No Obesity, No Diabetes?
Live Long and Prosper (and Be Bright Yellow at the Same Time)
Resveratrol (SRT501): Development Halted
Dapsone Prolongs Life? Well, In Nematodes It Does. . .
Does Resveratrol Really Work? And Does SRT1720?
GSK's Response to the Sirtuin Critics
Resveratrol (SRT501): Buy Now - Why Wait?
The Memory Goes Because. . .the Acetyl Groups Go?
SRT501 - A Trial Suspended
The Scent of Food Is Enough?
Sirtris's Compounds: Everyone Agrees?
Take These?
Rapamycin for Alzheimer's?
The Problem With Research on Aging
BioTime's Cellular Aging Results
A GSK/Sirtris Wrap-Up
A Storm in a Teacup
GSK and Sirtris: A Bit More
Sirtuin Scenarios
The Sirtris Compounds: Worthless? Really?
Caloric Restriction and Lifespan - Without the Caloric Restriction?
What Exactly Does Resveratrol Do?
A Nobel for Telomerase
mTOR, Rapamycin, and Lifespan: A Startling Study
Exercise and Vitamins: Now, Wait A Minute. . .
Resveratrol in Mice
Why Buy, Anyway?
$720 Million Worth of Sirtuin Research
Breaking the Contract of Aging
More Sirtuins With More Effects
And Thee, O Time
Sir2 Surprise
Klotho: Sooner Than You Think?
Breathing and Aging
When Natural Selection's Through With You - Part II
After Natural Selection's Through With You

Alzheimer's Disease
Tau Spreads On Its Own?
Bernard Munos Rides Again
Alzheimer's: The News Is Not Getting Better
Alzheimer's: Down With Amyloid?
Lilly's Gamma Secretase Inhibitor for Alzheimer's: Worse Than Nothing
Alzheimer's Markers and Collaboration
Alzheimer's and Amyloid, Again
Alzheimer's: Extracting Data From Failed Trials
The Memory Goes Because. . .the Acetyl Groups Go?
A Brief and Not At All Intemperate Evaluation of the Current Literature
Rapamycin for Alzheimer's?
Beta-Amyloid: An Antibiotic?
Dimebon, Grasping at Straws
Dimebon Comes Crashing to Earth
A Modest Literature Proposal
Dimebon for Alzheimer's: A Black Box Indeed
Two Doses of Crazy
An Alzheimer's Compound Runs Into Big Trouble
Short Topics From All Over
Amyloid in Trouble
Does Glucophage Make Alzheimer's Worse?
Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
Where Are the Drugs?
Rember for Alzheimer's: Methylene Blue's Comeback
Bapineuzumab: Good For Anything or Not?
Patents Stopping an Alzheimer's Wonder Drug?
Another Alzheimer's Compound Goes Down
Protecting Amyloid's Parent?
Elan Tries Again
In Which I Hate A Wonder Drug
Alzheimer's: A Report From the Front
ApoE4: Test or Not?
Fast Plaques in a Slow Disease
Checking The Numbers on the Alzheimer's Test
Beta-Secretase: Not So Fast?
Failure: Not Your Friend, But Definitely Your Companion
How Good Is Aricept, Anyway?
A Trial Too Far
Gumming Up the Amyloid Works
Silent Mutations and Noisy Ones
Back on the Air
Alzheimer's Vaccine Refuses to Die
Sleeping Dragons
Maybe They Can Formulate It in Madelaines
Who Dares, Wins?
Modeling the Brain?

Analytical Chemistry
Fluorine NMR: Why Not?
An NMR Poster
Proteins in a Living Cell
Fishing Around for Biomarkers
XMRV: It's Ugly, But That's Science
Detecting Single Cancer Cells
NASA's Arsenic Bacteria: A Call For Follow-Up Experiments
Enthalpy and Entropy Again
The Latest Technology
Chemical Biology: Plastic Antibodies?
Wisterone: A Structure I Can't Believe
Chemical Biology - The Future?
Running Your Fingers Over A Single Molecule
Floyd Landis: The Isotopes Weren't Lying, After All
Masses of Data, In Every Sample
Calorimetry: What Say You?
Sequenom: Strike Up the Music, Bring On the Cream Pies
The Infinitely Active Impurity
Sure About That?
Run It Past the Chemists
GE Healthcare's Idiotic Libel Suit
Faking X-Ray Structures. . .For Fun? Or Profit? Or What?
Water and Proteins Inside Cells: Sloshing Around, Or Not?
More Binding Site Weirdness
A Nobel for Ribosome Structure
Tie Me Molecule Down, Sport
The Great Acetonitrile Shortage
More Glowing Cells: Chemistry Comes Through Again
You Call That An X-Ray Source?
X-Ray Structures: Handle With Care
Start Small, Start Right
These Fragments I Have Shored Against My Ruins
Mass Spec on Mars
Floyd Landis: Could His Cortisone Treatments Exonerate Him?
Testosterone, Carbon Isotopes, and Floyd Landis
Doublets, Triplets, Whateverlets
Medicine Man

Animal Testing
The Mouse Trap
Reboxetine Doesn't Work. But That's Not the Real Problem.
Cancer Cells: Too Unstable For Fine Targeting?
Charles River Buys WuXi
Animal Studies: Are Too Many Never Published At All?
Fat Rats Make Poor Test Subjects?
Animal Testing: A View From the Labs
Animal Rights, You Say?
Animal Models: How High to Set the Bar?
Whose Guess Is Better?
The Animal Testing Hierarchy
Unacceptable
Less Than Zero
Worst Animal Model: Nominations Are Open
Formally Undecideable
Rats Rule, Right?
Ends, Means, Rats, and Dogs
Model Systems, From Inside and Out
Furry Judges, With Tails
What to Do When the Rats Die on You
Rats, For Fear of Worse
You'll Only Get Answers
Modeling the Brain?

Autism
What Autism Epidemic?
MMR Vaccine and Autism: Lies, All Lies
Vaccines in the Court
Autism and Vaccines: Boiling Over Yet Again
Thimerosal. Again.
Thimerosal, Again
A Mechanism for Thimerosal
Here and There
Compare and Contrast
The Rate of Autism
Clearance Sale
Thimerosal - A Chemical Point
Thimerosal - a Chemical Point
Clearance Sale
A Quick Tour Through the Mudhole
More on Autism (And Mercury)
More on Autism and Mercury
A Quick Tour Through the Mudhole
Neurotoxins
Neurotoxins
Doing Justice to Thimerosal, And the Story
Doing Justice to Thimerosal, and the Story

Biological News
Roche Goes Hostile for Illumina
Fun With Epigenetics
Warp Drive Bio: Best Name or Worst?
Osiris And Their Stem Cells
Brain Cells: Different From Each Other, But Similar to Something Else?
Proteins in a Living Cell
Geron, Stem-Cell Pioneers, Drop Stem Cells
Cyclodextrin's Day in the Sun
The Latest Sirtuin Controversy
Big Sirtuin News
Merck, RNAi, Alnylam, And So On
Bait And Switch For Type B GPCRs
A First Step Toward A New Form of Life
The Histamine Code, You Say?
The Uses of Disorder
Garage Biotech: The Book
Biomarkers, Revisited. Unfortunately.
Get Yer Telomeres Measured, Step Right Up
Smell The Vibrations? Fruit Flies Might Be Able To. . .
Fishing Around for Biomarkers
Arsenic Bacteria: Does The Evidence Hold Up?
Roche Has Problems - But RNA Interference Has More
And Now, the Retractome
Epigenetics: The Code Isn't The Object
TRIM21: A Cure For the Common Cold? Maybe Not. . .
Are Genes Patentable Or Not?
Laser Nematode Surgery!
More on Garage Biotech
Chemical Biology: Engineering Enzymes
Chemical Biology - The Future?
Vinca Alkaloids, And Where They End Up
Reverse-Engineering the Human Brain? Really?
Maybe We Should Make It More of a Game
Craig Venter, Venting
XMRV and Chronic Fatigue: You Thought You Were Confused Before
Stable Helical Peptides Can Do It All?
A Synthetic Genome; A New Species
Rosetta@Home
Curse of the Plastic Tubes
The Scent of Food Is Enough?
Homemade Morphine?
Masses of Data, In Every Sample
Let's Sequence These Guys
ACC2: Great Metabolic Target, Or Total Bust?
Rapamycin for Alzheimer's?
Sickened by an Engineered Virus?
What Do Nanoparticles Really Look Like?
GeneVec's Pancreatic Cancer Therapy Crashes
Nanoparticles and RNA: Now In Humans
A Bit More Garage Biotech
BioTime's Cellular Aging Results
Stem Cell Politics
The PSA Test for Prostate Cancer: Useless
Garage Biotech
A GSK/Sirtris Wrap-Up
Your Own Personal Bacteria
The Plasmid Committee Will See You Now
Biology By the Numbers
Enzymes and Fluorines
Receptors, Moving and Shaking
Maybe You Need Some More Testosterone Over There
An Enzyme Inhibitor You Have Never, Ever, Considered
Correlations, Lovely Correlations
MAGL: A New Cancer Target
Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
Extortion, Retractions, And More
Five Technologies For the Scrap Heap?
Run It Past the Chemists
Water and Proteins Inside Cells: Sloshing Around, Or Not?
What Exactly Does Resveratrol Do?
Nanotech Armor
Engineering Receptors: Not Quite There Yet. Not Exactly.
A Nobel for Ribosome Structure
A Nobel for Telomerase
Antioxidants and Cancer: Backwards?
Right Where You Want Them
Still Semaphoring, Even From the Bottom of the Swimming Pool
Schematic Notation for Biology?
Dealing With Hedgehog Screening Results
What's So Special About Ribose?
Genzyme's Virus Problems
Exercise and Vitamins: Now, Wait A Minute. . .
Niacin, No Longer Red-Faced?
No MAGIC Involved
Genes to Diseases: Hard Work, You Say?
The Motions of a Protein
Grabbing Onto A Protein's Surface
Gene Expression: You Haven't Been Thinking Big Enough?
Wash Your Tubes; Mess Up Your Data
System Biology: Ready, or Not?
Fructose In The Brain?
More Glowing Cells: Chemistry Comes Through Again
A Green Fluorescent Nobel Prize
Antipsychotics: Do They Work For A Completely Different Reason?
New, Improved DNA?
Receptors: Can't Live With 'Em, Can't Understand 'Em
Killing Proteins Wholesale
Empty As Can Be
Nanotech Stem Cells, Order Now!
RNA Interference: Even Trickier Than You Thought
Getting Real With Real Cells
Rainbows and Fishing Expeditions
Avandia: Going Under for the Third Time?
A Real Genetic Headscratcher
What We Don't Know About Enzymes
Checking The Numbers on the Alzheimer's Test
Let Us Now Turn To the Example of Yo' Mama
More Things Than Are Dreamt Of
Visfatin: Real Or Not?
It Went Up Instead of Down
Peptides as Texts
Neowater Replies
Nanotech Wonder Water?
Stem Cell Disaster
Grand Rounds Today, and Next Week
RNAi: The Awkward Age
Kinases and Their Komplications
The Vapor Trail I Referred To
It's a Bacterial Planet, You Know
There'd Better Not Be an Argon Receptor
All Bets Are Now Officially Off
A New Cancer Target - Maybe
Proteinocentrism
Gene Therapy Decisions

Birth of an Idea
Open Source Science?
Vial Thirty-Three, And More
Back on the Air
Vial Thirty-Three: Warp Drive
The Race Is On
Publish, Then Perish
The Horse Latitudes
Good News, Now That I Think About It!
Back To Life
Vial Thirty-Three: The Third Run
Vial Thirty-Three Rides Again
Vial Thirty-Three: One Up, One Down
Mid-day Update
Minute by Minute
Vial Number Thirty-Three
Cliff Diving
A Scientist's Resolutions
Report From What I Think is the Frontier
Experimental News
News Flash: I May Not Be a Fool
Data, At Last
Experimental Update
Experimental Update, For Those Who Care
Live The Stereotype!
The Consolations of Pure Research
Don't Talk To Yourself So Much
Mismatched Socks
A Little Ambiguity Would Be Welcome Right About Now
Dr. Lowe? I Have Your Hypothesis on Line Two
If This Doesn't Work, There's Only Reality To Fall Back On
Good News, Backing Slowly Through the Door?
Waiting for the Metaphorical Phone to Ring
Per Fits and Starts, Ad Astra
Here It Goes
Nature Stood Me Up
Close to the Vest
Close To the Vest
Experimental Update
In Case Anyone's Wondering
Back for More
Meanwhile, Back at the Chocolate Factory
The Nuts and Bolts of a New Idea
Measure Twice, Cut Once

Blink ›
Nature Doesn't Care: Latest in a Series
Vaccines by the Dozen
Follow Which Money Where?
An Experiment in Progress?
Alex Tabarrok on Me-Too Drugs

Blog Housekeeping
Comments (And Everything Else) Are Back
Comment Trouble
Ten Years of Science Blogging. Already?
Media Note
Holiday Break
Blog Traffic: A Thank-You
A "Things I Won't Work With" Request
Happy Thanksgiving
Lab Preparation: Key Lime Pie
Conferencing
Conference Travel, With Blogging
Day Off - Some Links and Some Ancient Greek
What An Offer
Back to Blogging
On and Off
Memorial Day
Inadvertent Day Off
Conference Time
Day Off
Another Snow Day
Snow and Chance Happeneth To Them All
Another Cold-Weather Recipe: Chicken Pot Pie
A Cold-Weather Recipe, By Request: Onion Soup
Weather Delay
Holiday Break
Blogging Break
Holiday Organic Synthesis: Chocolate Pecan Pie
Open Thread
Day Off
Blogroll Update
Housekeeping Note
Lunch at the Boston ACS Meeting
By The Way. . .
Out in the Public
Back in Business
Midsummer
More From the Fourth
Holiday
Nativis: In Which the Distant Footfalls of Lawyers Can Be Heard
Coming Soon
Chemistry In (Ahem) Everyday Life
Delivery Via Kindle
Of Cambridge, MA Interest Only
More on C&E News
Day Off
More Blogroll
Blogroll Update
Blog Traffic - Thanks!
Write A Book, Why Don't You
Twitter and Science, Revisited
Sure Thing
Physics, for Dogs and Others
Holiday Time Off
Day Off!
Another Blogroll Update
Light Blogging
Applied Organic Synthesis: Chocolate Pecan Pie
More For the Blogroll
A Blogroll Update
"Back to School"
Day Off
Traveling, Updates Later
Traffic Record
Back
Time to Sing the Alma Mater
H-h-h-holy C-c-c-c-cow
Blogroll Update
Return From Travel: A Note About Cheaptickets.com
Travel Continues. . .
Travel
Day Off
Blogroll Update
Proxy Server Update
Proxies for Iran (More Politics - Mixed With Technology)
And Now Some Politics
Quick Blogroll Update
Blog Contestification
Blog Contestiness
A Science Writing Award
Still More Blogroll Additions
Blogroll Update
More Travel!
San Diego
Travel
Blogs and Journalism
Hexacyclinol - Another Request
Day Off
The Blogroll
Holiday Break
How Slow is Research Today? Here's a Recipe!
Day Off
Back
Time Off
Happy Fourth of July
Leaving Comments: A Fix
Explaining It All
Quick Note
Anonymity?
Day Off
Commenting Issues
Back On the Air
Snow Day
Synthetic Prep of the Day: Chocolate Pecan Pie
Holiday Break
Bright Lights and Applause?
Blogroll Update
Meet the Blogger?
Not Necessarily So
Two Weeks Off
Real Life, Which Costs Real Money
But Enough About You
Blogroll Update
Linkage!
Back From DC
You Want Me to Just Talk? No Problem.
Comments on Comments
Blogroll Update
Back on the Air
Work At Home! It's Easy; It's Fun!
Holiday Schedule
Shameless Self-Promotion
Elsewhere
Watch This Space
Links and Such
Darn Photons
Here and There
A Friday Linkfest
Back on the Air
Travel
Linkorama
Missed One!
A Lengthy Day
Technical Difficulties
Blogroll Revamp
Various Updates
Comments Welcome - Really
Instead of Working
Procrastination Assistance
Outside Reading, and Plenty of It
And Another Thing. . .
Blogging About Science Blogging
Even More Worthwhile Stuff
Like, Er, Fine Wine. I Hope.
Summer Hours
Continued Slacking
Outside Reading
New Address
One Problem Solved, Anyway
A Technical Question
And Now A Word. . .
Schedule Update
Holiday Blogging
Stocking Stuffers, of a Sort
Now With The Great Taste of Fish
Comment Problems
Two Days Off (From This, Anyway)
No Coming Attractions Here
A Question For the Audience
Summer Hours
The Last Word on Taste
Categories
Welcome Back!
Catching Up
Here and There

Book Recommendations
Brain Cells: Different From Each Other, But Similar to Something Else?
A New Book on Chemical Patents
Data Handling in Collaborations
Book Review: The Quest for the Cure
Garage Biotech: The Book
Drug Discovery History
Serendipity in Medicine
Friday Book Recommendation
Friday Book Recommendation
A Friday Book Recommendation
Physics, for Dogs and Others
Recommended Books For Medicinal Chemists, Part One
Business Books: The Enantiomers
A Med-Chem Book Recommendation
Inspirational Reading?

Business and Markets
The Terrifying Cost of a New Drug
Buying Back Shares: An Admission of Defeat
AstraZeneca in Waltham
AstraZeneca Layoffs and Closings
AstraZeneca Cutting Even More?
Roche Goes Hostile for Illumina
Alnylam Cuts Back Hard
Takeda Announces Cuts
Warp Drive Bio: Best Name or Worst?
Newhouse Research
Sanofi's Bridgewater Site - Closing This Week?
Welcome To the Jungle! Here's Your Panther.
The JP Morgan Myths
SciFinder Access For the Unemployed
Osiris And Their Stem Cells
2012 In Startups
That's Sir Andrew to You
More From Hua - A Change of Business Plans?
Merry Christmas, Fred
AstraZeneca's Problems
Deals of the Year in Biopharma (Bonus: Names That Can't Happen)
More on Chinese Pharma Espionage
Chinese Pharma Espionage?
Pharma Overview
The Loss of the Middle (Drugs and the People Who Find Them)
Merck in China
Novartis: No More Neuroscience
More on Alex Denner
Acronym-Fest: GSK and Its DPUs
Worst Biotech CEO of 2011?
So What Did Lipitor Do for Pfizer? Or Its Shareholders?
Of Drug Research and Moneyball
Business Note: Random Promotion, Anyone?
Ray Firestone's Take On Pharma's Plight
Virtual Pharma, Revisited
Managing For Motivation, The Simple Way
Exit Icahn, Enter Denner?
Geron, Stem-Cell Pioneers, Drop Stem Cells
In-Sourcing Chemistry: Lilly and AMRI
Verastem Goes Public: Why Not?
Sanofi Announces Layoffs
Exelixis Fights City Hall, and City Hall Looks Like Winning
A Note About Identity Spoofing
Merck, And What Used to Be Schering-Plough
Novartis Announces Cutbacks
NCPharma: Changing the Drug Industry How, Exactly?
The Layoff Project
Abbott Cuts the Drug Business Loose
Reorg at Merck? (And a Complaint about Wall Street)
Amgen: Brace Yourselves
So, How Come You're So Darn Lucky, Eh?
What Layoffs Have Done
GSK and McLaren: Two Different Worlds
China's Home-Grown Insanity?
China's Pharma Ambitions: Hua Pharmaceuticals Responds
Chinese Pharma: No Shortage of Ambition, Anyway
The NIH Wonders About the Future of Biomedical Workers
Is Carl Icahn Going Away?
Lundbeck Cutting R&D
The Economics of the Drug Industry: Big Can't Be Big Enough?
Bernard Munos Rides Again
Dendreon: Watch the Cost Curve Being Bent
A Former Pfizer Executive Finally Trashes Pfizer's Strategy
Merck, RNAi, Alnylam, And So On
Merck Announces More Big Cutbacks
The Secret History of Pfizer
Innovation and Return (Europe vs. the US)
Pfizer Reverses Course in Sandwich - A Bit
Drug R&D Spending Now Down (But Look at the History)
Not Looking So Good At Eli Lilly (or AstraZeneca)
How's All That Cost-Cutting Working Out?
Block That Review
Another Two-Person Drug Company
Extreme Outsourcing
Pfizer's Brave New Med-Chem World
Pfizer's Layoff Dance
Get Yer Telomeres Measured, Step Right Up
Imperfect Pitch
Icahn's Biotech Adventure
A Look Inside the Compound Collections
Pfizer: Breaking Up Is Hard to Do
Merck: How to Spend the Money
Pfizer Layoffs Today
AstraZeneca Tears 'Em Down
Now They Tell Us
Nothing Personal
Merck and J&J Finally Come to Terms
Coming Up in the World With CROs
Total Pharma Job Cuts
R&D Is For Losers?
What's Really Killing Pharma
Westphal Leaves GSK
Insider Trading at the FDA
The Supreme Court Slams Big Pharma? Not Exactly.
The Small Drug Companies And the Big Ones
Brave New Office
More Bad News in the UK: Novartis Horsham
Pfizer Moves Antibacterials to Shanghai
Pfizer: Bigger, Um, Isn't Better?
What A Fool Believes
The Pfizer Air Force
The Costs of Drug Research: Beginning a Rebuttal
A Postdoc's Lament
MannKind: It's Not Looking Good
The Pfizer Sandwich Closure
Is Big Pharma Killing Startup Companies?
Want to Live Where Merck Used to Work?
Cutting The Cuts to Save Money on the Money-Saving
The Key Player in the Sanofi-Genzyme Deal Speaks Out
Merck, J&J, and Remicade: Waiting Nervously
The Top 200 Drugs
Fanapt: Not Paying Out
Too Much Outsourcing: Has the Line Been Crossed?
Whistleblowers: Paid Too Much?
Not Letting Pfizer's UK Site Go to Waste?
Merck's Strategy vs. Pfizer's
Pfizer's CEO Speaks
Pfizer Part Two: Cuts at Groton
Bad News: Pfizer Closes Site in Sandwich
Abbott's Cutting Jobs
Merck's Thrombin Antagonist In Trouble
Sanofi's Slow-Motion Takeover of Genzyme
Ahem: "Sell Gobs of Dope"?
The PhD Problem
How to Fund a Nonprofit Drug Company - And Others?
Jobs Roundtable Recap
Science Jobs Roundtable - Day Four
Chemistry Jobs Roundtable: What About Tenure?
Too Many PhDs, Revisited
Big Pharma's Lost Stock Market Decade
Chemistry Jobs, Present and Future
Have Pfizer's Investors Had Enough?
Exit Kindler
Novartis, Meet Novartis (Job Cuts or Not?)
More Advice From Andrew Witty
Of Deck Chairs, Six Sigma, And What Really Ails Us
Roche Has Problems - But RNA Interference Has More
Comment of the Day: Outsourcing and Architecture
An Outsourcing Blast
Where Drugs Come From: By Country
Where Drugs Come From: The Numbers
Merck vs. J&J: Wait For It
Exelixis Grabs A Life Preserver
The Layoff Picture
Spamming For Site Shutdowns. Sheesh.
Sanofi Goes Hostile
Sanofi-Aventis: It's $69/Share, And That's Where It Stays
Merck vs. J&J: It's Come to This, Eh?
Outsource to China, Then Move There?
China Outsourcing: Getting More Expensive, Fast?
Roche: Layoffs, or Rumors?
How About The Same Price You Turned Down Before? Hmm?
Sanofi-Aventis and Genzyme: Walking Away?
Going Hollywood
Reporting on Alternative Careers
Is Genzyme a Buyable Company At All?
MannKind and Seaside 88?
If You're Not A Chemist - What Next?
All Quiet on the Genzyme Front?
Know How to Make Praziquantel? Tell The World.
Charles River Gives Up
Let's Just Spread This Deal Out All Over the Paper, Why Don't We?
New from OSI / Astellas
Genzyme: On the Other Hand. . .
How Sleazy It Can Get
Genzyme Telling Sanofi-Aventis to Buzz Off?
Biosimilars: Not Easy, But Not Impossible, Either
Aventis: Is It Genzyme?
Hmmm: The Gates Foundation Bails
Lechleiter's Prescription for Science
Why Close One Research Site Over Another?
Merck Site Announcements - Closures and Otherwise
Drug Prices in the US: Not So High After All?
Sanofi-Aventis Acquires. . .Somebody?
GSK's Biotechy World
That Schering-Plough Lawsuit Isn't Going Away
Andrew Witty's Advice
Chemistry Employment in New England?
The Economic Impact of the Genomic Revolution's Failure
Checking the Business Ratios
Merck Layoffs - Underway?
Paying People to Take Their Medications
Eli Lilly, Meet Eli Lilly. Topic: Outsourcing!
Albany Molecular Cuts - In the US, Anyway
"Better Educated" in China?
India's Research Culture
Astellas and OSI: Nothing like MLNM/Takeda?
Manning the Phones
Astellas Buys Out OSI
Layoff at Takeda
China's Future
Perverse Incentives In Clinical Trials
Intermune: Right Back Down Again
Merck Rumors?
The Collapse of Complexity
Treatment INDs - For Any Generex Fans Out There
Sirtris's Compounds: Everyone Agrees?
Merck Closes a Site
Charles River Buys WuXi
Two Bad Ideas
Generex: Who Buys This Stuff, Anyway?
A Re-Org at Novartis
A Tiny Little Presentation Tip
Colchicine's Price Goes Through the Roof
Novartis, Roche Threaten To Leave the UK
Too Many Consulting Jobs Work This Way
Prediction Markets, Idea Sharing, and So On
The Crowd Goes Wild
Pfizer's Golden Age
Generex and Their Insulin Spray: Just Hype?
Let's Hope They're Right
Exelixis: Hmmmm.
If You Need Some Lab Equipment. . .
BioTime's Cellular Aging Results
Lilly Layoffs Today?
Intermune's Rise
Hope Darn Well Springs Eternal
Bad News at Exelixis
Merck/Schering-Plough People?
Twelve and One Half Per Cent
AstraZeneca Makes Its Move
Layoffs Coming at Eli Lilly?
Layoff News
Knocking on Doors
Merck Announces Cuts
Drug Patents in India
Picking Up Industrial Hires
Sanofi-Aventis Cuts Back
Where Would You Start a Company?
More On Pharma's Ugly Finances
Sheer Economics: How We Got in This Fix
BMS Freezes Salaries
GSK Day
And on the Carl Icahn Front. . .
GSK: More Cuts Coming
Merck and Sirna
Your First Pharma Bloodletting of 2010: AstraZeneca
Sequenom: Strike Up the Music, Bring On the Cream Pies
Honesty, Of A Sort
The Sirtris Compounds: Worthless? Really?
Carl Icahn Going For Genzyme?
Always Read the Fine Print
The Cost of New Drugs
Another Take on the Munos Paper
Munos On Big Companies and Small Ones
Pfizer's R&D Productivity
Drug Companies Since 1950
Pfizer's Pearl River Layoffs
Merck, Shopping in the UK?
Go Spread It On the Rosebushes
Against Panic
Telling the Layoff Story
Pfizer's Chemistry Head Count - Really?
Pfizer's Site Closures - An Analysis
Pfizer's New Layout
Selling It, And Selling It Hard
Thoughts on What Used to Be Schering-Plough
J&J Raises the Ax
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
Fifty Years of Scientific History For You
The Best Ones Aren't Over Here Any More?
You Mean You Don't Have to Buy Them?
Red Flags in Biotech
Pfizer's People
O Brave New World! That Has Such Companies In't!
What Pfizer Will Look Like in a Year
Short Topics From All Over
"Day One" at Pfizer
Which Pfizer / Wyeth Sites Will Close?
The Drug Business: A Turbulent Future?
Lilly Shrinks
Pharma Whistleblowing: How It Works
Sepracor: A Desirable Property?
A 2.3 Billion Dollar Attention-Getter
Lexapro, Forest Labs, and the Hard Sell
Drug Companies Are Polar Bears? Maybe Not.
Pharma's Return on Investment: Yikes
Ghostwriting
Savient Feels The Pains of Gout
Where Drugs Come From, and How. Once More, With A Roll of the Eyes
Drug Approvals, Natural And Unnatural
Incompetence, Avoided?
Too Many Scientists?
How Much Does the Drug Industry Spend on Marketing?
Vanda Comes Back From the Dead
Voluntary, You Say?
Meanwhile, Over At Sanofi-Aventis. . .
GSK's Getting Better. Just Ask the CEO.
One. . .Billion. . .Dollars!
Perpetual Patents: A Nasty Thought Occurs
CafePharma Will Now Approach The Bench
Will The Gentleman With the Pitchfork Please Speak Up?
A Deuterium Deal
Akt and Mek, But Not PDQ
Arena, Lorcaserin, and the FDA
J&J Lowers the Boom
Arena / Lorcaserin Update
San Francisco Biotech: Holding Up, or Not?
Goldman Sachs: Out Of the Drug Funding Business Already?
Kumbaya
Merck, Elsevier, and Fakery
Genentech: Let's Hope He's Right
Dendreon's Stock: What the Hey?
Dendreon's Revenge?
Pfizer's New Structure: Good Luck To All
Biogen Idec: What's Going On?
Layoffs At Merck
And That Is That
Roche / Genentech: The Chase Is Over
Merck/Schering-Plough: Waiting for J&J To Raise Their Hand
The Merck Deal and the SEC: Not a Joke
Merck Actually Does It
Single, Simple Numbers: Use At Your Own Risk
Genentech's Culture: At Risk or Not?
Business Books: The Enantiomers
Do Scientists Read Business Books? (Plus: Add a Circle to Dante's Inferno!)
Roche / Genentech: So There is a Deadline
How Long Is Roche Prepared to Wait?
Short Business Notes: AstraZeneca, Biogen, Vertex
Short Business Note: GSK's At Least Not Going to Merge
Sir James Black Vents, Therapeutically
Short Business Notes: Roche/Genentech, Sanofi-Aventis, GSK
Roche Goes Hostile - Or Does It?
Opportunity Costs
Pfizer and the Credit Crunch
Pfizer / Wyeth: Different This Time?
Pfizer / Wyeth: They're Going to Take Us All Down With Them
Nitromed: Someone Wants Them
With A Straight Face, Yet
Lilly Pays the Price
More on Pfizer's Layoffs
Why Pfizer?
Layoffs. More Layoffs.
Insider Trading in Drug Stocks? Not Unknown. . .
The Worst Biotech CEO?
Pfizer's Restructuring Grinds Along
Goldman Sachs: A New Drug Research Model?
Roche Stalls For Time
Two Drugs in One? Maybe Not.
The Back Door to the Stock Market
Pfizer: Strategy, Layoffs, and Money
Lilly And Imclone: Not Expensive Enough!
Cutbacks - But Not As Bad This Time
Merck Cuts Back (Again)
Imclone Really Does Get Bought
Eli Lilly and Imclone: Sensible? Real?
Hard Times: A Manifesto
Various Drug Industry News, None of It All That Good
Imclone's Secret Admirer
Pfizer: As We Speak?
Ranbaxy: Cutting Corners, or Falsely Accused?
BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
US and UK Biotech: Growth and Form
Pfizer / Bayer?
Direct To Consumer Ads: Wasted Money?
RNAi: Bubble or Not?
Genentech and Roche, Act Two
Roche Palo Alto: What's Going On?
Job Seekers: Genentech, GSK, and Elsewhere
GSK Layoffs: Yes, Again
Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
Should Genentech Be a Part of Roche?
Vytorin: Another Round of Nasty Results
Sharing the Enlightenment
More on Outsourcing
Pfizer's Prospects: Just Ducky
Alli: "Underwhelming"
Suits vs. Lab Coats?
More On the GSK Layoffs
GSK: Money-Green Outside, Pink-Slip Inside
A Breath of Fresh Air from Fuji
Nullius in Verba
Awash in Yen
Cordaptive Q and A
Why Buy, Anyway?
$720 Million Worth of Sirtuin Research
Free Sushi in the Cafeteria!
A Solution, Courtesy of the MIT Faculty
Hits, Misses, and Some More Misses
How Many PPIs Does the World Need?
Drugs and Money
Laissez-Faire?
Cheap Happiness
Drugs and Money and How It Feels
Dollar, Drugs, and Advertising
Top of the Heap
Hearing Footsteps
Biogen's Not For Buying. For Now.
Med-Chem Layoffs, On the Front Page
More Belts Tighten
How You Doin'? How's Everybody Doin'?
Lights, Camera, Pharma!
Come On. Improve, Already.
Surveying the Exubera Crater
Biogen on the Block?
More Layoffs, And What They Might Mean
Hey, Graduates! Negotiate Hard, You Hear, Now?
Good News From the HR Department!
Have We Got A Deal For You!
Guess That Market
Oh, Come On
Ah, Rumors
Buying What You Can't Make? Or What?
Exubera Spirals Toward the Drainpipe
European Drugs, American Drugs
Knowing What You Know. . .
Alas, Dendreon
Outsourcing Blues?
Put Your Money Down
Layoffs - Again
Amgen: The Pythian Oracle Laughs Again
Buy! Sell! Shout! Moan!
Vaccines Everywhere
Vectibix Lurches A Bit
Schering-Plough Goes Shopping
Biotech's Net Loss?
A Good Day's Work
Good Sense Breaks Out, Film at Eleven?
BMY-SNY?
The Big Picture
Pfizer's Pfinances
Novo Nordisk Axes Med-Chem
ICOS In Pieces?
Pfizer's Sizing
Sell! (It's Not Just Me)
Help Wanted - I Hope
Chinese Med-Chem - In China, For Once
Hope, Springing Eternal And All That
You Can't Make Money If You Don't Get Paid
Blow The Trumpets
Up Periscope And Fire All Bow Tubes
Imclone, Drama Queen of Biotech
Tough Targets
Walking the Plank at Bristol-Myers Squibb
Merck: Unfigure-outable
The Great Plavix Disaster
Pfizer's Man at the Top
Pfizer Recalculates
The Sun Shines at Pfizer
Getting and Spending
J&J Shrinks Their Labs Again
Neurocrine's Choice
The Fur Continues to Fly
What's German For "Food Fight"?
Leadership Secrets of the Data Fudgers
Full Disclosure
Golden Parachute, Still Packed and Ready
Rioting for Unemployment
Can You Say "Uebernahmeangebot"?
Nitromed's Slow Decline
More on Outsourcing
J&J Shakes Things Up
Forecast: Rain, Eventually
Imclone Revisited
The Tar Pit Beckons
James Cramer, Biocryst, and You
Human Genome Science Hits the Wall
Where Do the Good Ones Go?
The Check Shows Up in the Mail. Really.
Pfizer Opens Their Wallet - Again
You Figure It Out
Public Utility, You Say?
Punching the Clock at Merck
What Ails the Germans?
The Globalization of Med-Chem
Drug versus Stock
Waiting for the FDA
Glaxo v. Pfizer: Sales Force Stand-Down?
Pfizer's Prospects
Maybe They Should Fire Them All?
Optioning the Drug Portfolio
Don't Ask; Just Trade
Let's See What the Sharks Think of These Steaks!
Could I Have a Side Order of Risk With That?
Public Utility, You Say?
How Bad Are the Cox-2 Inhibitors, Anyway?
A Day With All the Bark Left On It
Rank and Yank?
Measure for Mismeasure
Around and About
Another Shot Across the Bow
Vox Populi
As Goes ASCO. . .
A Capacious Rat-Hole Indeed
Deferred Gratification Is Better Than None At All
Yahoots
Foaming Up Over the Edge
Bulking Up
Thou Hast It Now. . .
Play It Again
Tasty New Recipes for the Root of All Evil
Quis custodiet ipsos custodes?
Pravachol vs. Lipitor Update
Mismatched Socks
Ignorance Was Bliss
I will do such things - What they are yet I know not. . .
Allons Pharmas de la Patrie!
. . .Your Huddled Pharmas Yearning to Breath Free
Ah, Marketing
Mismeasure for Mismeasure
Measure for Measure
What Sort of Number Did You Have in Mind?
O Brave New Market, That Has Such Medicines In It
Bad News at a Bad Hour of the Night
Caveat Lector
Muddying the Water For Fun and Profit
Back For Some More
Marketing Ueber Alles
By Any Other Name
The Apatosaurus. The Spruce Goose. The Pyramids
The Irish Elk. The Mongol Empire. And Other Things That Got Too Big to Work Well.
A Less-Than-Subtle Plan

Cancer
Academia and Industry, Suing Each Other
(Un)stoppable Pixantrone
Zelboraf: Treat One Cancer, Speed Up Another?
Fun With Epigenetics
AstraZeneca's Problems
Burzynski Revisited
Podcast on Avastin
The Burzynski Cancer Treatment
The Mouse Trap
Avastin Coverage, Amended
Avastin's Metastatic Breast Cancer Approval Revoked
Brain Cells: Different From Each Other, But Similar to Something Else?
Geron, Stem-Cell Pioneers, Drop Stem Cells
Verastem Goes Public: Why Not?
Medivation Comes Through With MDV3100
Exelixis Fights City Hall, and City Hall Looks Like Winning
Avastin: False Hope for Metastatic Breast Cancer
Too Many Cancer Drugs? Too Few? About Right?
So, How Come You're So Darn Lucky, Eh?
Terra Slightly Less Incognita
A Startlingly Good Leukemia Trial
More On Cancer Drug Shortages
Dendreon: Watch the Cost Curve Being Bent
The Duke Cancer Scandal and Personalized Medicine
Avastin and Medicare
Avastin At the FDA Today: Passion Should Lose
The Evolution of Resistance: Are We Doing It Wrong?
A Shortage of Cancer Drugs?
The Ethics of Avastin
Off the Beaten Track. Way, Way, Off.
More Zeroing In On Breast Cancer Cells
So, You Thought Breast Cancer Was Complicated?
Oncology Follow-Up Trials
New Cures! Faster! Faster!
Sanofi's PARP1 Inhibitor Misses
Not Enough Progress Against Cancer?
Detecting Single Cancer Cells
The Avastin Decision: A Reality Check
Resveratrol (SRT501): Development Halted
Halaven: Holder of the Record
Is Cancer A Disease of the Modern World?
Princeton's New Chemistry Building
PLX4032: The Good News and the Bad News
Metformin Against Cancer?
Avastin For Metastatic Breast Cancer: The Whole Story
Avastin: Taking It Back
Cancer Cells: Too Unstable For Fine Targeting?
Exelixis Gets a Compound Back
Mylotarg and the FDA
Angiotensin Receptor Blockers and Cancer: For Real?
Ipilimumab (And Progress Against Cancer)
Again, What's It Worth to You?
Eribulin Gets Reviewed, Finally
The Power of Photons, You Say?
DCA And Cancer: More Results
Malcolm Gladwell on Synta and Oncology
Environmental Cancer?
Perverse Incentives In Clinical Trials
SRT501 - A Trial Suspended
Masses of Data, In Every Sample
GeneVec's Pancreatic Cancer Therapy Crashes
Antisoma's Phase III Disaster
Diminishing Returns
The Problem With Research on Aging
Nanoparticles and RNA: Now In Humans
The PSA Test for Prostate Cancer: Useless
HER2 Confusion
The Front Lines of Cancer Treatment
MAGL: A New Cancer Target
Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
A Nobel for Telomerase
Antioxidants and Cancer: Backwards?
Thalidomide for Myeloma: Whose Idea Was It?
Wasted Money, Wasted Time?
Avastin's Numbers
Akt and Mek, But Not PDQ
But You Can't Make Them Take It?
Angiogenesis Inhibitors: Helping or Hurting?
Into the Clinic. And Right Back Out.
Dendreon's Stock: What the Hey?
Dendreon's Revenge?
The Motions of a Protein
Kinases: Hot or Not?
Curse Of the Lost Compounds
Sunesis: No Substitutions Allowed?
BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
The Complicated Causes of Cancer
GSK Layoffs: Yes, Again
Vytorin: Another Round of Nasty Results
Auroral Activity
And You Thought Exubera Was A Disaster Before
Whose Guess Is Better?
Judah Folkman
Plants For Cancer?
Bacterial Infection: Better Or Worse Than Cancer?
Arsenic, Patents, and the World
The Current Cancer Long-Jump Record
Phase Zero?
Let A Thousand Flowers Bloom
Amgen: The Pythian Oracle Laughs Again
Awful, No Doubt. But Not As Awful as Before?
Vaccines Everywhere
Failure: Not Your Friend, But Definitely Your Companion
Vectibix Lurches A Bit
A Good Day's Work
Good Mistakes?
An Innocent Question
Reality, Here In This Little Dish
Sell! (It's Not Just Me)
Blow The Trumpets
Here and There
Imclone, Drama Queen of Biotech
Tell 'Em You Work On Something Else
Resistance Isn't Quite Futile
That Fount of Information We Call ASCO
Jungle Rot
New Frontiers in Self-Deception
Price Gouging or Not?
Gold and Lasers
What's It Worth to You?
Mice, Humans, and Cancer
Another Shot at Cancer
The Hard News on Cancer
Hype or Hope?
No Such Disease
Selectivity: One of Those Flexible Concepts
A Tale of Two Trials
Cancer Delusions
When the Alternative is Nothing
Biotech At Last, Eh?
That Has to Be Good, Right?
ASCO Fever
'Tis the Season
The Price of Desperation
Targretin's Troubles
Drug versus Stock
Still Not All That Easy
Springtime for Oncology
What We Are Pleased to Call State of the Art
Black Friday: One Damn Thing After Another
The Coming Oncology
Check, Please
Tarceva Targets
Clay Lies Still, But Blood's A Rover
Costs and Benefits, Risks and Rewards
Another Shot Across the Bow
Bungee Jumping with PPAR Drugs
It'll Cost You
Vox Populi
As Goes ASCO. . .
All the Myriad Ways
Deferred Gratification Is Better Than None At All
Yahoots
Foaming Up Over the Edge
A New Cancer Target - Maybe
Back on the Air
Pneumonia, of All Things
O Brave New Market, That Has Such Medicines In It
Not Even Funny
Genetic Optimism
The Wall Street Journal versus the FDA
Consequences of Aneuploidy
Aneuploidy, or What're A Few Chromosomes, More or Less?
HER-1 And HER-2, Too
Save Your Tears
A Few Words
Did He Say What They Thought He Said?
Now Is the Peptide of Our Discontent
Hype and Glory
More Imclone, More Food for Thought
A Certain Tension in the Air
Imclone in Progress

Cardiovascular Disease
Lipitor Expiration Day
Regeneron Finally Makes It to the Market
Pushing Onwards with CETP: The Big Money and the Big Risks
Geron, Stem-Cell Pioneers, Drop Stem Cells
Anticoagulants, One After Another
A Few More Victories Like This, And We Will Be Undone
Cardiac Hope and Cardiac Hype
Niacin's Unexpected Flop
Fenofibrate: Good For Much?
Phase II Failures
Merck's Vorapaxar: Bleeding, Indeed
Merck's Thrombin Antagonist In Trouble
Merck's CETP Compound: Still Alive, But The Big Fun Awaits
Apotex's Plavix Adventure: Four Years Later
Avandia: Was the Evidence Buried?
That Schering-Plough Lawsuit Isn't Going Away
Lilly's Statin - Yes, It Is 2010
Angiotensin Receptor Blockers and Cancer: For Real?
Raising Your HDL - Through the Brain?
Pfizer Halts a Trial Early - On Good News
Steve Nissen vs. GlaxoSmithKline
Animal Studies: Are Too Many Never Published At All?
Diminishing Returns
Tricor's Troubles
Steve Nissen's Meeting with GSK
Remember Apo-A1 Milano? Pfizer Does.
Plavix vs. Effient
Zetia Takes Another Torpedo
Placebos Can Work the Other Way, Too
Statin Safety?
Rolofylline Hits the Skids
CafePharma Will Now Approach The Bench
Mipomersen - It Still Works
Exercise and Vitamins: Now, Wait A Minute. . .
Farewell to ACAT, and to Lots of Time and Money, Too
Niacin, No Longer Red-Faced?
The Polypill Rides Again
Takeda Gets A Surprise
Torcetrapib: What Was the Problem? And Does It Matter?
Crestor: Would It Save Any Lives?
Crestor: Risks Up, Risks Down
Prasugrel Today?
Vytorin: Another Round of Nasty Results
Prasugrel: Come Back This Fall
Merck, Vioxx: Seventeen and Three
In Which I Hate A Wonder Drug
Cordaptive Q and A
Another Cholesterol Medication Goes Down (Or Does It)?
Whose Guess Is Better?
Vytorin Numbers
Vytorin: It's A Pity
Pfizer vs. the NEJM: A Legal Showdown
Off Target? Which Target Did You Mean?
A Look Under the Hood
Vytorin, Holed Under the Waterline
Renin, Wherefore Art Thou, Renin?
Rimonabant, Out In the Light
The Avandia Wars Continue
More Avandia, And More on Marketing
Avandia: Trouble or Not?
The HDL Compost Pile
AGI-1067: Dead or Alive?
Torcetrapib: The Foil-Lined Hat Perspective
Bigger And Greasier
Too Near the Sun?
The Torcetrapib Catastrophe
Pfizer's Sizing
Ah, the Heck With the Error Bars
Elsewhere
It Should Work. It Just Doesn't.
Plavix Plot Twists
Merck: Unfigure-outable
The Great Plavix Disaster
Pfizer Recalculates
More Statin Skirmishing
Vioxx: 18 Months to Trouble?
As Merck Caroms Off Another Tree
Merck and the Numbers
Merck's Latest Underwhelming Data
The New England Journal And Its PR Flacks
Merck, So Far
Nitromed's Slow Decline
The Big Statin Pillow Fight
NEJM vs. Its Contributors, Round Two
Merck versus the New England Journal
Does Celebrex Have A Future At All?
An Expensive Way Back for Celebrex
The New England Journal of Legal Immunity?
Selectivity: One of Those Flexible Concepts
Merck on Trial
Where's the Combo?
A Drug's Target, Finally
COX-2 Aftermath
Waiting for the FDA
Boarding Up the Windows
The FDA Weighs In
Let's See What the Sharks Think of These Steaks!
Cox-2 Confusion
How Bad Are the Cox-2 Inhibitors, Anyway?
More on Merck
A Day With All the Bark Left On It
The Last Word (For A While) On Me-Too Drugs
Me Too, Part Two
Clinical Trials And What to Do With Them
Pravachol vs. Lipitor Update
Ignorance Was Bliss
Ezetimibe, The Press, and More
The Beginning? It's Right Past the End. . .
Sic Transit Gloria Mundi
Trials of Trials
Cholesterol Lowering, One Way or Another

Chem/Bio Warfare
The Litvinenko Case: More On Polonium and Alpha Particles
Evil Thoughts of Evil Things
A Fire, And Its Flames
Osmium Tetroxide, Of All Things
Ricin Redux
More Ricin
Ricin
And While We're On the Subject - Mercury?
A Mystery Gas?
Chemical Warfare, Part Five: The Real World
Chemical Warfare, Part Four: More On Nerve Agents and Their Chemistry
Chemical Warfare, Part Three: How Nerve Agents Work
Chemical Warfare, Part Two: Lethal Agents (Other Than Nerve Gas)
Chemical Warfare, Part One: Introduction

Chemical Biology
Screening Quickly Through the Mutants
A First Step Toward A New Form of Life
Chemical Biology: Engineering Enzymes
Chemical Biology: Plastic Antibodies?

Chemical News
Glass Structure, Atom by Atom
Potassium Hydride Is Not Your Friend
Lead-Oriented Synthesis - What Might That Be?
The UCLA Lab Fatality: Criminal Charges Filed
Chemistry, The Movie!
Trifluoromethylation, The Easy Way?
An NMR Poster
Now That's A Catalyst
Nothing Says "Chemistry" Like Nonsense!
Finding Even More New Reactions By Looking For them
Georgia Tech Forgets How to Draw Structures
Brow-Furrowing Chemical Ads
A Quasicrystal Nobel Prize
Pulling Molecules Apart, For Fun
Finding New Reactions By Looking For Them
Terra Slightly Less Incognita
Fifty Years of Med-Chem Molecules: What Are They Telling Us?
Get Yer Rhodanines Here
Crazy Shape-Shifting Bullvalenes
New Ways to Fluorinate
Bait And Switch For Type B GPCRs
Precious Metal Time
The Public Perception of Chemistry
Will Macrocycles Get It Done?
Getting Rid of Pesky Chirality
Like Charges, Er, Attract?
Quis Custodiet Ipso Custodes?
Process Chemistry Makes the Headlines
In Memoriam, Two Chemists
What Medicinal Chemists Really Make
In Which I Do Not Lose It, For Once
Smell The Vibrations? Fruit Flies Might Be Able To. . .
The Solid Phase
Not On My Street - I Hope
Going to Let Someone Else Do This One
Halaven: Holder of the Record
Finally, An Alternative to Palladium. About Time.
ACS Survey - Or Something Else?
Graphene Oxide as a Reagent
Princeton's New Chemistry Building
Back to Philadelphia
Meeting Time
A Nobel For Palladium Couplings, At Last
Chemical Biology: Engineering Enzymes
Chemical Biology: Plastic Antibodies?
Wisterone: A Structure I Can't Believe
Nobel Season 2010
Delightful, But It Apparently Works
Chemical Biology - The Future?
Synthetic Chemistry: All Mined Out?
Want To Make an Amide? Have I Got Good News For You!
Sodium Hydride As Oxidant, Again?
Ancient Chemistry Comes Back to Life?
Organic Chemistry: A Lack of Challenges?
Metal-Free Coupling Reactions: Now Wait A Minute. . .
Running Your Fingers Over A Single Molecule
Know How to Make Praziquantel? Tell The World.
Another Zero-Palladium Delusion?
The Ideal Synthesis
Maitotoxin: It's On, All Right
Sparteine and Other Fine Chemical Shortages
Max Gergel's Memoirs
What's the Condensation Record?
Pyridines and Dichloromethane
You Don't See Many Names Starting with "Tellura-"
Maitotoxin Revisited
Report from C&E News
Nonsense About LSD
Flowing, Not So Gently
Together At Last
Sure About That?
More Binding Site Weirdness
K. C. Nicolaou, Call Your Office
Hoist, Petard, Etc.
Retire These Reactions!
Microwaves Aren't Magic
Nobel Season 2009
Chew On This, Enzyme
More on T2, and Degrees
175 Times. And Then the Catastrophe.
"Scratch and Sniff" Turns Into "Zap and React"
Another Iron Reaction Hits The Mat
Rings of the Future!
Everything In Its Place
The Further In You Go, The Bigger It Gets
Devils, Metals, and Details
TMS Diazomethane: Update On a Fatality
Writing With Triazoles
The Motions of a Protein
Grabbing Onto A Protein's Surface
Your Paper Is A Sack Of Raving Nonsense. Thank You.
Hexacyclinol - Another Request
Hexacyclinol: A Forensic Case
The Original Nanotechnology
A Long Tail Indeed
The Real Hazards of the Lab
The Great Acetonitrile Shortage
Diversity-Oriented Synthesis: Oriented The Right Way?
Short Items: Viral NMR, Alarming Rings, Cheap Reading, Etc.
An Impressive Nanolist of Nanocitations
Copper: A Gentleman's Disagreement
New Tricks With Glassware
DNA Forklifts, DNA Pliers
Le Dernier Cri
One For the Brave
Ertl Wins: Down With Witchcraft
All Sorts of Holes
Steve Ley, Azadirachtin, and Me (Very Much in That Order)
ACS Meetings
Calcium: A Backwater
Smell the Vibrations
Six Chem-Geek Questions
Hexacyclinol Rides Again
Hexacyclinol? Or Not?
Chem-Geek Alternate History
A New Route to Tamiflu?
More on Woodward
Archaeologists Announce Dirty Laundry Discovery
Why Total Synthesis?
Climbing Mountains

Clinical Trials
Reaction to Andy Grove's Clinical Trial Proposals
Rexahn Rides Again
Targacept's Antidepressant Fails, And How
Medivation Comes Through With MDV3100
Exelixis Fights City Hall, and City Hall Looks Like Winning
Too Many Cancer Drugs? Too Few? About Right?
Andy Grove's Idea For Opening Up Clinical Trials
Bernard Munos Rides Again
Laquinimod Fails For Multiple Sclerosis
The Duke Cancer Scandal and Personalized Medicine
An Unethical Clinical Trial
Making the Numbers Confess
Niacin's Unexpected Flop
The Ethics of Avastin
Fenofibrate: Good For Much?
Phase II Failures
Lucentis and Avastin: Results
Update on Avastin and Lucentis
More on KV and Makena's Pricing
Makena's Price: What to Do?
The Cost to Develop a Drug: Your Own Numbers?
That $43 Million R&D Figure
The Costs of Drug Research: Beginning a Rebuttal
Use Avastin! Don't Use Avastin!
Down In Phase III. Again.
Oncology Follow-Up Trials
Sanofi's PARP1 Inhibitor Misses
Not Enough Progress Against Cancer?
Merck's Vorapaxar: Bleeding, Indeed
Reboxetine Doesn't Work. But That's Not the Real Problem.
Merck's Thrombin Antagonist In Trouble
Detecting Single Cancer Cells
Resveratrol (SRT501): Development Halted
Of Deck Chairs, Six Sigma, And What Really Ails Us
Merck's CETP Compound: Still Alive, But The Big Fun Awaits
Trusting the Medical Literature?
Avastin: Taking It Back
Cancer Cells: Too Unstable For Fine Targeting?
Alzheimer's Markers and Collaboration
Resveratrol (SRT501): Buy Now - Why Wait?
Alzheimer's and Amyloid, Again
Vivus, Qnexa, Arena, Lorcaserin and the FDA
Avandia: Was the Evidence Buried?
Alzheimer's: Extracting Data From Failed Trials
Pfizer Halts a Trial Early - On Good News
DCA And Cancer: More Results
Perverse Incentives In Clinical Trials
Steve Nissen vs. GlaxoSmithKline
SRT501 - A Trial Suspended
A Landmark In Clinical Trial Data Interpretation
Ardea's Gout Drug Progresses
Animal Studies: Are Too Many Never Published At All?
GeneVec's Pancreatic Cancer Therapy Crashes
Antisoma's Phase III Disaster
Diminishing Returns
Nanoparticles and RNA: Now In Humans
Benford's Law, Revisited
Tricor's Troubles
Intermune's Rise
Hope Darn Well Springs Eternal
Dimebon, Grasping at Straws
Dimebon Comes Crashing to Earth
HER2 Confusion
Steve Nissen's Meeting with GSK
The Front Lines of Cancer Treatment
Dimebon for Alzheimer's: A Black Box Indeed
A Database of Side Effects
Correlations, Lovely Correlations
Sirtuin Scenarios
Lilly's R&D Outsourcing
An Alzheimer's Compound Runs Into Big Trouble
All Of You Industrial Scientists: Out Of the Room
Plavix vs. Effient
Zetia Takes Another Torpedo
Massaging the Data for Neurontin?
Placebos Can Work the Other Way, Too
Arzoxifene: Not the Road to Big Profits?
Wasted Money, Wasted Time?
Amyloid in Trouble
Medarex, Ipilimumab, Prostate Cancer, And Reality
Avastin's Numbers
Rolofylline Hits the Skids
CafePharma Will Now Approach The Bench
Akt and Mek, But Not PDQ
Arena, Lorcaserin, and the FDA
Surrogate Markers Are Awful, But They're Ours
Goldman Sachs: Out Of the Drug Funding Business Already?
Into the Clinic. And Right Back Out.
Farewell to ACAT, and to Lots of Time and Money, Too
Another Obesity Drug? Not Likely.
Lilly's Latest Loses (This Time)
And While We're Talking About Industry-Sponsored Studies. . .
What Results Did You Have In Mind?
Drug Industry Research: Reliable or Not?
Want A Hard Disease Target? Try Lupus
Maribavir, Ouch
New Year - I Hope!
Goldman Sachs: A New Drug Research Model?
Torcetrapib: What Was the Problem? And Does It Matter?
Avandia: Trouble, Run Head to Head
Two Drugs in One? Maybe Not.
Crestor: Would It Save Any Lives?
Crestor: Risks Up, Risks Down
Down The Chute in Phase III
Rember for Alzheimer's: Methylene Blue's Comeback
Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
Vytorin: Another Round of Nasty Results
Glaxo Asks the Eurocrats
Another Alzheimer's Compound Goes Down
Fun With Bacteria
And You Thought Exubera Was A Disaster Before
Another Cholesterol Medication Goes Down (Or Does It)?
Vytorin: It's A Pity
You Get What You Pay For?
Taranabant in Trouble?
Hits, Misses, and Some More Misses
Antidepressants: Depressing News or Not?
A Look Under the Hood
Vytorin, Holed Under the Waterline
Come On. Improve, Already.
Deactivation, After All
Rimonabant: Down to Earth
Rimonabant, Out In the Light
Phase Zero?
Pecunia Non Olet?
The Avandia Wars Continue
Knowing What You Know. . .
Avandia: Trouble or Not?
Deep Breaths
Vectibix Lurches A Bit
FDA Advisory Panels: Pay, No Play
AGI-1067: Dead or Alive?
Vertex, Hepatitis, and Gripping the Arms of Your Chair
Upside Down Activity
Torcetrapib: The Foil-Lined Hat Perspective
Too Near the Sun?
The Torcetrapib Catastrophe
It Should Work. It Just Doesn't.
A Spray-Painted Crystal Ball
Tough Targets
Tegenero, In Detail
Vioxx: 18 Months to Trouble?
Formally Undecideable
A Question For the Crowd
Access to Phase I Drugs: A Constitutional Right?
A Word to the Wise About TGN1412
TNG1412: Was There a Warning?
Update on TGN1412
No Immunity From Immunity
But His Name Lives On. . .
The FDA Loosens Its Tie
An Expensive Way Back for Celebrex
Rigel's Puzzling Failure
This Had Better Be Good
By a Nose in a Head to Head
No Clear Winners
Muraglitazar's Turn
Gritting Our Teeth
Where's the Combo?
Still Not All That Easy
The NIH in the Clinic
One More On Basic Research and the Clinic
How It Really Works
Unburied
Me Too, Part Two
Clinical Trials And What to Do With Them
Fast, Cheap, and Sometimes Even Good
Primum Non Nocere, Eh?
The Journals Fight Back
Your One-Stop Clinical Data Superstore?
Cue the Music
Pravachol vs. Lipitor Update
Ignorance Was Bliss
More From the Me-Too Front
Putting A Price on Proving It
Here and There
Trials of Trials
Statins and Multiple Sclerosis
Muddying the Water For Fun and Profit
Save Your Tears

Closing Time
Med-Chem Layoffs, On the Front Page
Massachusetts Moving
A Post I've Been Looking Forward to For Months
Layoffs - Again
More Help Wanted?
Have We Got a Job For You!
A Break, Whether I Felt Like It Or Not
Open For Business
Ghost Town
Out With the Old
Cleans Down to What Should Be the Shine
Hi, My Name Is [...]
The Paper Mountain
Vial Thirty-Three: Warp Drive
Where Do All The Chemicals Go?
The Race Is On

Current Events
Science, A Zero-Sum World, and the State of the Union
More on Chinese Pharma Espionage
The Force of Cluelessness
A Brief Note on Current Events
A Radiation Chart to Clip and Save
Potassium Iodide Pills
Quick Japan Update
Bias And How to Deal With It
Japan
Science and Revolution
Health Care Reform and the Drug Industry: How Goes It?
And a Quick Political Note
Lethal Injection: A Case For the FDA?
Martin Gardner, RIP
Floyd Landis: The Isotopes Weren't Lying, After All
Report from C&E News
Bits And Pieces
Sir James Black, 1924-2010
The Health Care Bill: A Therapeutic Rant
Theft at Eli Lilly
Pharma and the Health Care Bill: Value For the Money?
Sanofi-Aventis Cuts Back
Here's a Business Plan For You
GSK Day
A Scorched-Earth Policy at Wyeth's Princeton Site?
GE Healthcare's Idiotic Libel Suit
Once You Have Paid Him the Danegeld. . .
Climategate and Scientific Conduct
Warren DeLano
Prof. Keith Fagnou
Against Panic
A Nobel for Ribosome Structure
A Nobel for Telomerase
The Details of the Baucus Bill
Pay Them Now, Or Pay For It Later
Norman Borlaug
The PhRMA Deal
PhRMA's Negotiating Game
Health Care Reform - Really?
Iran: Politics and Technology Update
Proxy Server Update
Proxies and Politics Again
Politics: Proxy Servers Revisited
Proxies for Iran (More Politics - Mixed With Technology)
And Now Some Politics
Will The Gentleman With the Pitchfork Please Speak Up?
But You Can't Make Them Take It?
Kumbaya
Faking It on Facebook
Don't Hit The Bunkers Just Yet
Biogen Idec: What's Going On?
Sponsor A Gene?
Layoffs At Merck
Greedy Biotechs?
Wyeth v. Levine: Pre-emption Goes Away
Ranbaxy in Trouble
Single, Simple Numbers: Use At Your Own Risk
Autism and Vaccines: Boiling Over Yet Again
Their Crime? Collaborating With Other Scientists. . .
Short Items: India, Sanjay Gupta, Satori Pharmaceuticals
Well, Hose Me Down. . .
Layoffs. More Layoffs.
Pfizer's Restructuring Grinds Along
We Interrupt This Science. . .For Some Politics
BlackLight Power Responds
Blacklight Power: What on Earth?
A Green Fluorescent Nobel Prize
Nobel Season 2008
Pfizer: As We Speak?
More Pfizer Layoffs?
Nullius in Verba
Judah Folkman
Ah, Politics
Unnatural, And Proud Of It
Ertl Wins: Down With Witchcraft
Nobel Chemistry Odds
Nobel Season
The Choir Hears It Again
Pour Encourager Les Autres
Access To Science
Time To Conduct Some Business
Layoffs - Again
Hedgehogs in Stockholm
F. A. Cotton, 1930-2007
CMPI Conference: Critical Path
CMPI Conference: Lunch With the FDA
CMPI Conference: Panel on the Politics of Drug Evaluation
CMPI Conference: Panel on Media Coverage
That Smell
And The Winner Is. . .
Injustice
The Litvinenko Case: More On Polonium and Alpha Particles
Polonium Poisoning
Help Wanted - I Hope
Here and There
Floyd Landis: Could His Cortisone Treatments Exonerate Him?
Airplanes and Chemicals
Testosterone, Carbon Isotopes, and Floyd Landis
Explosion News
Poor Put-Upon Intelligent Design
The Dover Decision Comes Down
Merck Update
Merck, Finally
Intelligent Design, Molecule By Molecule
The Dover Decision
Merck Off the Mat
Metathesis Nobel!
A Piece of the Action
Okay, One More Merck Point
No More Merck For A Couple of Days
Judgement Day
Welcome to the World, I Hope
Strangers on a Train
Special Off-Topic Weekend Irrelevancy
Actually, It's Everything Else That's Off-Topic
Happy Fourth of July
Osmium Tetroxide, Of All Things
And Another Thing. . .

Diabetes and Obesity
Dapagliflozin Goes Down (For the Last Time?)
More From Hua - A Change of Business Plans?
Regeneron Finally Makes It to the Market
SRT1720: Good (And Confusing) News for Obese Mice
mINDY Mice - No Obesity, No Diabetes?
GSK and Alli. Not Quite Working Out
MannKind: It's Not Looking Good
Lorcaserin's Complete Response
Avandia Goes Down: A Research Rant
Live-Blogging Arena's FDA Committee Hearing
Lorcaserin in Trouble
MannKind and Seaside 88?
PPAR: A Veil Is Lifted, At Last
Vivus, Qnexa, Arena, Lorcaserin and the FDA
Avandia: Was the Evidence Buried?
Insulin Degrading Enzyme's Turn in the Spotlight
Steve Nissen vs. GlaxoSmithKline
Treatment INDs - For Any Generex Fans Out There
Generex: Who Buys This Stuff, Anyway?
The Crowd Goes Wild
ACC2: Great Metabolic Target, Or Total Bust?
Generex and Their Insulin Spray: Just Hype?
Rats and High-Fructose Corn Syrup
Tricor's Troubles
Your Own Personal Bacteria
Steve Nissen's Meeting with GSK
Avandia: Off the Market or Not?
Sirtuin Scenarios
Gaining and Losing and Discovering and Selling
MAGL: A New Cancer Target
Obesity: Hope Springs Eternal (Summer 2009 Version)
Obesity Shows Up in the Death Rate? Right?
Arena, Lorcaserin, and the FDA
Arena / Lorcaserin Update
Exercise and Vitamins: Now, Wait A Minute. . .
A DPP-IV Compound Makes It Through
Another Obesity Drug? Not Likely.
Takeda Gets A Surprise
Does Glucophage Make Alzheimer's Worse?
Avandia: Trouble, Run Head to Head
CB-1 Obesity Drugs: Farewell to the Whole Lot
Fructose In The Brain?
Taranabant Is No More
Metabolic Hope Springs Eternal
All The Fat Cells You'll Ever Have - Sort Of
Alli: "Underwhelming"
Merck Bails on Natural Products
Why Buy, Anyway?
Exubera, Safety, and No Guarantees
And You Thought Exubera Was A Disaster Before
Whose Guess Is Better?
Taranabant in Trouble?
Off Target? Which Target Did You Mean?
More On Merck and Taranabant
What You Become Known For
Eat It, Breath It, Soak in It?
Avandia: Going Under for the Third Time?
Bad Luck For Novartis - And For Diabetics
Depressing Figures for Acomplia
Surveying the Exubera Crater
More Things Than Are Dreamt Of
Buying What You Can't Make? Or What?
Exubera Spirals Toward the Drainpipe
Deactivation, After All
Visfatin: Real Or Not?
Right Down the Alli
Rimonabant: Down to Earth
Rimonabant, Out In the Light
The Avandia Wars Continue
More Avandia, And More on Marketing
Avandia: Trouble or Not?
Exubera: This Time With Feeling
Rimonabant, Slowly
You Can't Make Money If You Don't Get Paid
Up Periscope And Fire All Bow Tubes
The Inscrutable French
Neuropeptide Y Dies, But It Never Surrenders
Tell 'Em You Work On Something Else
Rimonabant Arrives
What's French for "Trust Us"?
Rimonabant Bangs Into. . .Something
Pfizer Takes a Deep Breath
Ghrelin and Obestatin
Pargluva Goes Down?
This Had Better Be Good
Waiting for Pargluva
Muraglitazar's Turn
Gritting Our Teeth
Symlin, At Last
Worries about Rimonabant?
Bungee Jumping with PPAR Drugs
Why Own the Car, When You Can Own the Road?
Ah, Marketing
Of All Sad Words. . .
Fighting City Hall
A Treadmill Pill?
Enzymes, Right and Wrong

Drug Assays
The Infinitely Active Impurity
Fluorine NMR: Why Not?
Do We Believe These Things, Or Not?
Lead-Oriented Synthesis - What Might That Be?
Riding to the Rescue of Rhodanines
Rating A Massive Pile of Compounds
Francis Collins Speaks
Does Anyone Want the NIH's Drug Screening Program?
Different Drug Companies Make Rather Different Compounds
Lilly's Open Screening Program: An Update
Get Yer Rhodanines Here
How Many New Drug Targets Aren't Even Real?
Kibdelomycin, A New Antibiotic. In A Way.
Is Anyone Doing the Pfizer Screening Deal?
Bait And Switch For Type B GPCRs
Phenotypic Screening For the Win
In Which I Do Not Lose It, For Once
A Look Inside the Compound Collections
Fragments Versus DOS: A Showdown
The NIH's New Drug Discovery Center: Heading Into the Swamp?
And One Was Just Right?
Enthalpy and Entropy Again
Laser Nematode Surgery!
A Cautionary Tale
Chemical Biology: Plastic Antibodies?
GSK's Response to the Sirtuin Critics
Natural Products: Not the Best Fit for Drugs?
Masses of Data, In Every Sample
Charles River Buys WuXi
Take These?
Animal Studies: Are Too Many Never Published At All?
Compounds and Proteins
Privileged Scaffolds? How About Unprivileged Ones?
Privileged Scaffolds
Drugs And Their Starting Points
We Don't Know Beans About Biotin
Tricor's Troubles
Garage Biotech
Why You Don't Want to Make Death-Star-Sized Drugs
Calorimetry: What Say You?
Two For One Sale
Polluting the Literature with PAINs
Merck and Sirna
The Infinitely Active Impurity
GSK and Sirtris: A Bit More
The Sirtris Compounds: Worthless? Really?
Run It Past the Chemists
Selective Scaffolds
Why Don't We Have More Protein-Protein Drug Molecules?
More Binding Site Weirdness
Side Effects, Predicted?
Lumpy Assay Results
What Exactly Does Resveratrol Do?
To What End?
Dealing With Hedgehog Screening Results
Drug Approvals, Natural And Unnatural
Why Does Screening Work At All? (Free Business Proposal Included!)
Eli Lilly Gives It Away
More Hot Air From Me on Screening
Want To Screen Pfizer's Compounds? Sign Here.
No MAGIC Involved
Drugs For Bacteria: Really That Hard, Or Not?
Tie Me Molecule Down, Sport
Structure-Activity: Lather, Rinse, and Repeat
The Hideous Numbers of Compounds
Diversity-Oriented Synthesis: Oriented The Right Way?
Sticking It to Proteins
Wash Your Tubes; Mess Up Your Data
Animal Models: How High to Set the Bar?
X-Ray Structures: Handle With Care
Receptors: Can't Live With 'Em, Can't Understand 'Em
Sharing the Enlightenment
Oops
The Miracle Solvent
Whose Guess Is Better?
Start Small, Start Right
Getting Real With Real Cells
The Animal Testing Hierarchy
These Fragments I Have Shored Against My Ruins
A Bad Assay: Better Than None?
Let Us Now Turn To the Example of Yo' Mama
The Current Cancer Long-Jump Record
Travels In Numerica Deserta
Less Than Zero
No Shortcuts
Good Mistakes?
Upside Down Activity
Reality, Here In This Little Dish
The Unattractive Truth
Those Darn Invisible Creatures
Waste O' Time Awards
More on Voodoo
And 0.04 Molar in Eye of Newt. . .
Everything's Under Control, Right?
Seven Questions
What Makes A Target, Anyway?
Compounds for the Sake of Compounds
Oh, Dear
Too Interesting For Us
Model Systems, From Inside and Out
What Ails Us
The Vapor Trail I Referred To
Our Cheerful Buddy, The Cell Membrane
Ezetimibe, The Press, and More
The Beginning? It's Right Past the End. . .
How Drugs Die
A Request From Biology
Ratio Rationalizations
That Voodoo That We Do

Drug Development
The Terrifying Cost of a New Drug
Putting a Number on Chemical Beauty
Fun With Epigenetics
Biogen: A "Decimated" Pipeline?
Welcome To the Jungle! Here's Your Panther.
Do We Believe These Things, Or Not?
Lead-Oriented Synthesis - What Might That Be?
More From Hua - A Change of Business Plans?
The Sirtuin Saga
Drugs, Airplanes, and Radios
Riding to the Rescue of Rhodanines
Pushing Onwards with CETP: The Big Money and the Big Risks
"You Guys Don’t Do Innovation. The iPad. That’s Innovative"
Francis Collins Speaks
A Note to Andy Grove
Harvard to the Rescue
Too Many Cancer Drugs? Too Few? About Right?
Different Drug Companies Make Rather Different Compounds
How Many New Drug Targets Aren't Even Real?
GlaxoSmithKline Reviews the Troops
Chinese Pharma: No Shortage of Ambition, Anyway
Bernard Munos Rides Again
2011 Drug Approvals Are Up: We Rule, Right?
Will Macrocycles Get It Done?
Phenotypic Screening For the Win
Innovation and Return (Europe vs. the US)
Drug R&D Spending Now Down (But Look at the History)
What Translational Research Should Academia Do?
Extreme Outsourcing
Pfizer's Brave New Med-Chem World
Maybe It Really Is That Hard?
Imperfect Pitch
Process Chemistry Makes the Headlines
What Medicinal Chemists Really Make
Translation Needed
Off the Beaten Track. Way, Way, Off.
R&D Is For Losers?
Your Comments on the NIH's CNS Drug Program?
The NIH Goes For the Gusto
Value in Structure?
More on KV and Makena's Pricing
Makena's Price: What to Do?
The Cost to Develop a Drug: Your Own Numbers?
That $43 Million R&D Figure
The Costs of Drug Research: Beginning a Rebuttal
Down In Phase III. Again.
Gonna Focus on Re-Engineering the Tools for the Process
New Cures! Faster! Faster!
Drug Problems: A Diagnosis
Fragments Versus DOS: A Showdown
The NIH's New Drug Discovery Center: Heading Into the Swamp?
What's the Most Worthwhile New Drug Since 1990?
Oh, And While You're At It. . .
Merck's Vorapaxar: Bleeding, Indeed
Merck's Thrombin Antagonist In Trouble
Gassing Your Crystals
How to Fund a Nonprofit Drug Company - And Others?
More Advice From Andrew Witty
Of Deck Chairs, Six Sigma, And What Really Ails Us
And One Was Just Right?
Where Drugs Come From: By Country
Where Drugs Come From: The Numbers
Trusting the Medical Literature?
Chemical Biology: Engineering Enzymes
Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual?
GSK's Response to the Sirtuin Critics
Going Hollywood
Cancer Cells: Too Unstable For Fine Targeting?
Open-Source Pharmaceutical Babble
Fungal Structures to the Rescue
Exelixis Gets a Compound Back
Flibanserin: Not a "Female Viagra" At All
The Economic Impact of the Genomic Revolution's Failure
The Atlantic Monthly on Drug Pipelines
Another Set of Eyes
Biosimilars: Not So Dang Easy
Malcolm Gladwell on Synta and Oncology
Perverse Incentives In Clinical Trials
The Collapse of Complexity
Rosetta@Home
Pfizer's Future: Biotech Followups
Charles River Buys WuXi
A Landmark In Clinical Trial Data Interpretation
Pfizer's Golden Age
Drugs And Their Starting Points
Merck and Sirna
Sirtuin Scenarios
The Cost of New Drugs
Another Take on the Munos Paper
Munos On Big Companies and Small Ones
Pfizer's R&D Productivity
Selective Scaffolds
All Of You Industrial Scientists: Out Of the Room
Recommended Books For Medicinal Chemists, Part One
Ozonides As Drugs: What Will They Think of Next?
O Brave New World! That Has Such Companies In't!
The Drug Business: A Turbulent Future?
Industrial Research: More Grounded in Reality, or Not?
To What End?
Thalidomide for Myeloma: Whose Idea Was It?
Polymorphs and Salts: India Raises an Eyebrow
Arzoxifene: Not the Road to Big Profits?
Spray-Painted For Success
Pharma's Return on Investment: Yikes
Drug Approvals, Natural And Unnatural
How Much Does the Drug Industry Spend on Marketing?
Eli Lilly Gives It Away
Medarex, Ipilimumab, Prostate Cancer, And Reality
One. . .Billion. . .Dollars!
Funky Carbocycles
Genzyme's Virus Problems
More Hot Air From Me on Screening
The View From Pfizer's Corner Offices
Ugliness Defined
A Deuterium Deal
Akt and Mek, But Not PDQ
Deuterated Drugs: The PTO Says OK, So Far
The NIH Takes the Plunge
Goldman Sachs: Out Of the Drug Funding Business Already?
Farewell to ACAT, and to Lots of Time and Money, Too
An HIV Drug. Or A Gout Drug? Or Both. . .
The Mechanical Chemist?
Two! Two! Two Drugs in One!
Gene Expression: You Haven't Been Thinking Big Enough?
Your Paper Is A Sack Of Raving Nonsense. Thank You.
Single, Simple Numbers: Use At Your Own Risk
Heavy Atoms, Heavy Profits?
A Med-Chem Book Recommendation
Kinases: Hot or Not?
Open Pharma?
Opportunity Costs
New Year - I Hope!
Goldman Sachs: A New Drug Research Model?
Curse Of the Lost Compounds
Prodrugs: How the Pros Do It?
Noisy Numbers
CB-1 Obesity Drugs: Farewell to the Whole Lot
Down The Chute in Phase III
Animal Models: How High to Set the Bar?
Where Are the Drugs?
Taranabant Is No More
The Complicated Causes of Cancer
Samurai! Unleash Your Drug Candidates!
Sticky Containers, Vanishing Drugs
Replacing What's Being Lost
Confident
Sharing the Enlightenment
Glaxo Asks the Eurocrats
Lurching Around For Fun and Profit
In Which I Hate A Wonder Drug
"Not Useful" Means "Not Approvable", Right?
Cordaptive Q and A
Exubera, Safety, and No Guarantees
Pre-emption For Real?
Another Cholesterol Medication Goes Down (Or Does It)?
Whose Guess Is Better?
RNA Interference: Even Trickier Than You Thought
Getting To Lyrica
That's Never Gonna Work
Now Your Liver Doesn't Have to Make It For You
A Solution, Courtesy of the MIT Faculty
Dissolve Your Troubles Away
Off Target? Which Target Did You Mean?
What You Become Known For
Getting Real With Real Cells
A Look Under the Hood
The Animal Testing Hierarchy
Eat It, Breath It, Soak in It?
The EU Suspects No One, And Suspects Everyone
Rainbows and Fishing Expeditions
Plants For Cancer?
A Bad Assay: Better Than None?
Bad Luck For Novartis - And For Diabetics
Then I Felt Like Some Watcher of the Skies. . .
You Do The Easy Stuff; I'll Do the Easier
Quiz Time!
Here Be Chiral Dragons, With Fluorinated Fangs
Reasons to Be Different
Lights, Camera, Pharma!
Andy Grove: Rich, Famous, Smart and Wrong
Nerve, Lots and Lots of Nerve
Resistant Little Creatures
Bacterial Infection: Better Or Worse Than Cancer?
Come On. Improve, Already.
Ugly, But Useful
Arsenic, Patents, and the World
Don't Step Over It, Even If It's Right in Front of You
Drugs From Where?
Guess That Market
Renin, Wherefore Art Thou, Renin?
Elbow Room
Like Clockwork
Winning, By Tying Losers Together
Here, Fix This, Would You?
Run! Anthropologists!
You Discover It, We Sell It. Deal?
From the Sequencer to the Drugstore?
Deactivation, After All
A Farewell to Tin
Bigger, Tougher, Longer? Or Not?
Less Than Zero
Awful, No Doubt. But Not As Awful as Before?
Failure: Not Your Friend, But Definitely Your Companion
The HDL Compost Pile
Naked Synthesis
FDA Advisory Panels: Pay, No Play
AGI-1067: Dead or Alive?
No Shortcuts
Quietly Disappearing From the Skies
There's Toxicity and There's Toxicity
Going Hollywood, For Our Own Good?
What Can Academia Do?
The Big Picture
Upside Down Activity
Reality, Here In This Little Dish
Bigger And Greasier
Hope, Springing Eternal And All That
Experimental Compound Codes
The Unattractive Truth
Peptides as Texts
More Handedness
A Spray-Painted Crystal Ball
Ray Kurzweil's Future
The Sun Shines at Pfizer
Fuzeon's Fallout
Disapproval of Approvability
A Natural Wonder Drug - Now What?
Have The Rules Changed?
All Natural
Heart-Warming Stories of Success
Kinase Inhibitors: Doomed From the Start?
If It's Not One Thing. . .
What Makes an Ugly Molecule?
Five Questions
Out the Door and Over the Edge
Selectivity: One of Those Flexible Concepts
Another Thing You'd Think Would Be Simple
Seven Questions
Morphine in the Brain: Go For It, or Not?
How Much Success?
Modeling the Modelers
Tailfins and All
Knocking Opportunity Costs
The Globalization of Med-Chem
Bigger and Greasier
How'd We End Up Here, Anyway?
Hope in a Drum
The Novartis Way
Model Systems, From Inside and Out
Finishing, And Starting
Proteins to the Rescue?
DNA to Drug?
More on Merck
Drug Development: The Current Odds
The NIH in the Clinic
One More On Basic Research and the Clinic
How Much Basic Research?
How It Really Works
Me Too, Part Two
Down in the Salt Mine
How Long Can This Go On?
Worries about Rimonabant?
Bungee Jumping with PPAR Drugs
The Two Ends of the Stick
Down the Hatch
What Ails Us
Odd Elements in Drugs: Silicon
The Vapor Trail I Referred To
Stuart Schreiber on Stuart Schreiber
The March of Folly Leader Board
How Drugs Die
Sic Transit Gloria Mundi
New! Improved! Now With Stickier Lumps!
What Sort of Number Did You Have in Mind?
Structure-Inactivity Relationship Would Be More Like It
You Don't Hear "Eureka" That Often
They All Get Real at Some Point
Our Buddies at the FDA
What to Do When the Rats Die on You
A Twisty Road
Another Shot
It's Not Pretty, But It Works
What's a Project Manager to Do?

Drug Industry History
The Terrifying Cost of a New Drug
Putting a Number on Chemical Beauty
Nowhere to Go But Up?
The Sirtuin Saga
Pharma Overview
Drugs, Airplanes, and Radios
The Loss of the Middle (Drugs and the People Who Find Them)
Naming Your Company After Yourself
Lipitor Expiration Day
So What Did Lipitor Do for Pfizer? Or Its Shareholders?
Regeneron Finally Makes It to the Market
Of Drug Research and Moneyball
Two From Glaxo's Old Days
Ray Firestone's Take On Pharma's Plight
Virtual Pharma, Revisited
Merck, And What Used to Be Schering-Plough
Too Many Cancer Drugs? Too Few? About Right?
Different Drug Companies Make Rather Different Compounds
Ah, Remember Those Days? How Will We Remember These?
What Layoffs Have Done
Targets to Avoid (Or That We Wish We Had)
Fifty Years of Med-Chem Molecules: What Are They Telling Us?
A Dish Best Served Cold
GlaxoSmithKline Reviews the Troops
Chinese Pharma: No Shortage of Ambition, Anyway
The Economics of the Drug Industry: Big Can't Be Big Enough?
Read the Comments
Bernard Munos Rides Again
A Former Pfizer Executive Finally Trashes Pfizer's Strategy
Merck Moving Research From Rahway?
2011 Drug Approvals Are Up: We Rule, Right?
The Secret History of Pfizer
Phenotypic Screening For the Win
Innovation and Return (Europe vs. the US)
The Histamine Code, You Say?
Drug R&D Spending Now Down (But Look at the History)
Extreme Outsourcing
Pfizer's Brave New Med-Chem World
Maybe It Really Is That Hard?
Ups and Downs
A Look Inside the Compound Collections
Pfizer: Breaking Up Is Hard to Do
R&D Is For Losers?
What's Really Killing Pharma
Value in Structure?
The Small Drug Companies And the Big Ones
Pfizer: Bigger, Um, Isn't Better?
The Costs of Drug Research: Beginning a Rebuttal
Drug Problems: A Diagnosis
The Top 200 Drugs
Too Much Outsourcing: Has the Line Been Crossed?
Merck's Strategy vs. Pfizer's
The NIH's New Drug Discovery Center: Heading Into the Swamp?
What's the Most Worthwhile New Drug Since 1990?
How to Fund a Nonprofit Drug Company - And Others?
And So, 2011
Big Pharma's Lost Stock Market Decade
Have Pfizer's Investors Had Enough?
More Advice From Andrew Witty
Of Deck Chairs, Six Sigma, And What Really Ails Us
Halaven: Holder of the Record
Comment of the Day: Outsourcing and Architecture
Where Drugs Come From: By Country
Where Drugs Come From: The Numbers
Well, Okay: The Ugliest Biopharma Sites?
Most Picturesque Biopharma Location?
Drug Discovery History
Princeton's New Chemistry Building
Serendipity in Medicine
Avandia Goes Down: A Research Rant
Columns Outside The Doors
Going Hollywood
Not The End. Not At All
Open-Source Pharmaceutical Babble
Natural Products: Not the Best Fit for Drugs?
GSK's Biotechy World
The Economic Impact of the Genomic Revolution's Failure
Looking Back at the Genome
Alzheimer's: Extracting Data From Failed Trials
The Atlantic Monthly on Drug Pipelines
Insulin Degrading Enzyme's Turn in the Spotlight
Malcolm Gladwell on Synta and Oncology
The Collapse of Complexity
Two Bad Ideas
Colchicine's Price Goes Through the Roof
Too Many Consulting Jobs Work This Way
Diminishing Returns
Privileged Scaffolds? How About Unprivileged Ones?
Privileged Scaffolds
Where Would You Start a Company?
More On Pharma's Ugly Finances
Polluting the Literature with PAINs
Sheer Economics: How We Got in This Fix
Remember Apo-A1 Milano? Pfizer Does.
The Cost of New Drugs
Another Take on the Munos Paper
Munos On Big Companies and Small Ones
Pfizer's R&D Productivity
Drug Companies Since 1950
Why Don't We Have More Protein-Protein Drug Molecules?
Against Panic
Thoughts on What Used to Be Schering-Plough
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
Fifty Years of Scientific History For You
You Mean You Don't Have to Buy Them?
O Brave New World! That Has Such Companies In't!
Fall From Grace
The Drug Business: A Turbulent Future?
Sepracor: A Desirable Property?
Rings of the Future!
Thalidomide for Myeloma: Whose Idea Was It?
Drug Companies Are Polar Bears? Maybe Not.
Spray-Painted For Success
Pharma's Return on Investment: Yikes
Where Drugs Come From, and How. Once More, With A Roll of the Eyes
Amyloid in Trouble
Drug Approvals, Natural And Unnatural
Why Does Screening Work At All? (Free Business Proposal Included!)
How Much Does the Drug Industry Spend on Marketing?
Jargon Will Save Us All
GSK's Getting Better. Just Ask the CEO.
The View From Pfizer's Corner Offices
CafePharma Will Now Approach The Bench
Akt and Mek, But Not PDQ
The NIH Takes the Plunge
San Francisco Biotech: Holding Up, or Not?
Book Review Department
Farewell to ACAT, and to Lots of Time and Money, Too
Genes to Diseases: Hard Work, You Say?
Who They?
Scientists Running Your Drug Company?
The Mechanical Chemist?
The Equipment Graveyard
Drugs For Bacteria: Really That Hard, Or Not?
Roche / Genentech: The Chase Is Over
Merck Actually Does It
Does Glucophage Make Alzheimer's Worse?
Kinases: Hot or Not?
Sir James Black Vents, Therapeutically
A Long Tail Indeed
Ten Years After: The Genomics Frenzy
Why Pfizer?
New Year - I Hope!
When Placebos Were All There Were
Curse Of the Lost Compounds
Novartis and Reality
Down The Chute in Phase III
Where Are the Drugs?
Sunesis: No Substitutions Allowed?
Replacing What's Being Lost
Confident
Pfizer's Prospects: Just Ducky
A Breath of Fresh Air from Fuji
Awash in Yen
Lurching Around For Fun and Profit
Merck Bails on Natural Products
O Pioneers!
Why Buy, Anyway?
That's Never Gonna Work
Pen and Paper
Hits, Misses, and Some More Misses
Smaller, Wetter, Harder to Work With
What You Become Known For
Judah Folkman
Plants For Cancer?
Top of the Heap
Hearing Footsteps
Med-Chem Layoffs, On the Front Page
Then I Felt Like Some Watcher of the Skies. . .
One Year
Reasons to Be Different
Lights, Camera, Pharma!
Andy Grove: Rich, Famous, Smart and Wrong
Surveying the Exubera Crater
More Layoffs, And What They Might Mean
Good News From the HR Department!
The Good Old CombiChem Days
Guess That Market
Renin, Wherefore Art Thou, Renin?
You Discover It, We Sell It. Deal?
From the Sequencer to the Drugstore?
Godzilla vs. Mothra? Relman vs. Epstein!
First Impressions
Bigger, Tougher, Longer? Or Not?
Awful, No Doubt. But Not As Awful as Before?
Biotech's Net Loss?
Going Hollywood, For Our Own Good?
The Big Picture
Way Out Here
Novo Nordisk Axes Med-Chem
Good Stuff and Bad Stuff
The Paper Mountain
Help Wanted - I Hope
Naming of Names
Experimental Compound Codes
Peter Kim, So Far
Chem-Geek Alternate History
All Natural
Why All the Gloom?
Procter and Gamble Throws in the Towel
But At My Back I Always Hear. . .
Serono's Suitors
The Old Stuff
The Painful History of Substance P
Room At the Top?
Biotech At Last, Eh?
Days of Silicon and Roses
Some Perspective
Merck's State of Mind
Different or Not? You Tell Me.
Pharma Flock Begins Migration
Circular Mistakes
How Much Basic Research?
The State of the State of the Art
Loose Lips
Dumpster Diving for Data?
What Ails Us
The Last Word on Taste
The March of Folly Leader Board
The March of Folly
Reality's Revenge
Ezetimibe, The Press, and More
The Beginning? It's Right Past the End. . .
The Old Days, Some Older Than Others
Here and There
Thalidomide in the Mirror
Overpatenting?
Where Credit's Due
And I Still Have Some of Those Shirts
Fun While It Lasted
Nothing Like It in the World
Separation Anxiety

Drug Prices
The Terrifying Cost of a New Drug
Makena's Market. Or Lack of One.
More On Cancer Drug Shortages
Does Anyone Want Axanum?
Dendreon: Watch the Cost Curve Being Bent
Drugs for Multiple Sclerosis: Worth the Price, Or Not?
Avastin and Medicare
Process Chemistry Makes the Headlines
Lucentis and Avastin: Results
Update on Avastin and Lucentis
KV Pharmaceuticals and Makena: The FDA's Move
More on KV and Makena's Pricing
Makena's Price: What to Do?
The Cost to Develop a Drug: Your Own Numbers?
That $43 Million R&D Figure
The Costs of Drug Research: Beginning a Rebuttal
Use Avastin! Don't Use Avastin!
Avastin For Metastatic Breast Cancer: The Whole Story
Going Hollywood
Drug Prices in the US: Not So High After All?
Ipilimumab (And Progress Against Cancer)
Again, What's It Worth to You?
Pfizer's Future: Biotech Followups
Colchicine's Price Goes Through the Roof
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
Fall From Grace
Lexapro, Forest Labs, and the Hard Sell
The PhRMA Deal
PhRMA's Negotiating Game
Just Give It to NIH
Health Care Reform - Really?
Book Review Department
Kumbaya
Direct To Consumer Ads: Wasted Money?
A Solution, Courtesy of the MIT Faculty
Drugs and Money
Laissez-Faire?
The EU Suspects No One, And Suspects Everyone
Drugs and Money and How It Feels
Dollar, Drugs, and Advertising
Guess That Market
Godzilla vs. Mothra? Relman vs. Epstein!
European Drugs, American Drugs
Brazil Raises The Pirate Flag
Fuzeon's Fallout
Price Gouging or Not?
What's It Worth to You?
Pfizer Takes a Deep Breath
Ugly, But Effective
The Undefeated Brazilian Team
Brazil Pulls Out the Pin
Check, Please
Cui Bono?
Preach It, Brother
Prices and Innovation
Peter Rost, Oddity
Kicking the Dinosaur's Tail - Again
Me Too, Part Two
I'll Have the Price They're Having
John Kerry on Drug Prices
Costs and Benefits, Risks and Rewards
So What's Wrong With A Little Money Changing Hands?
It'll Cost You
You'd Think It Was An Election Year or Something
Price Hydraulics
Getting the Word Out, For Once
Welding the Steering Wheel
More From the Me-Too Front
Putting A Price on Proving It
One Of Us Is Hallucinating
Reimportation's Just the Beginning
Drug Prices and Costs - From the Mail
More on Prices, High and Otherwise
The Contact Sport of Cost Accounting
Darn Those R&D Costs, Anyway
From Each According To Their Creativity, To Each According To Their Difficulty?
The Pricing Weapon
Good Sense Wins a Round
More on Drug Prices
The Dismal Science of Drug Prices

General Scientific News
Let's Start Off the Meeting With An Ad, OK?
Strangest Presentation You've Seen?
Worst Lecture of All, Or Greatest?
What's the Hardest Thing?
Very Likely Not Real, But Still. . .(The E-Cat)
Liquid Handling
The Singularity, Postponed
Podcast Interview on Drug Discovery
Yep, That's A Nobel Prize, Right There
Chemistry Nobel Time
The NIH Wonders About the Future of Biomedical Workers
Gilenya's Price
Return of the Arsenic Bacterium
A Google Oddity
Ups and Downs
Writing About Science, and Liking It
Politics in the Lab
NASA's Arsenic Bacteria: A Call For Follow-Up Experiments
Arsenic Bacteria: Does The Evidence Hold Up?
Kitchen Chemistry Gear
Is Cancer A Disease of the Modern World?
So, How Well Does Winning a Nobel Set You Up?
Nobel Season 2010
Chemical Biology - The Future?
Know How to Make Praziquantel? Tell The World.
Lechleiter's Prescription for Science
Let's Sequence These Guys
Try It At Home
Garage Biotech
A Friday Book Recommendation
Maybe You Need Some More Testosterone Over There
Find That Pattern
Pass the Popcorn
Copyright 1671: I Like the Sound of That
Climategate and Scientific Conduct
Real Electrons
Real Molecules
Jargon Will Save Us All
Altermune - Real Stuff or Not?
The Mechanical Chemist?
Fan Mail
Tie Me Molecule Down, Sport
Science and Its Values
Short Items: Viral NMR, Alarming Rings, Cheap Reading, Etc.
Awkward Conversations
Enhancing the Brain: Here We Go
Protein Folding: Complexity to Make More Complexity?
The Gates Foundation: Dissatisfied With Results?
Nullius in Verba
An Eye For the Numbers
Science By Country
Getting Smarter Already?
DNA Forklifts, DNA Pliers
Room At The Bottom, For Sure
And Speaking of Discovering Things. . .
Dumber in English?
Enzyme Humility
Unnatural, And Proud Of It
Winning, By Tying Losers Together
Hype In Spaaaace!
The Chamber of DNA Secrets
The Big Time
Naked Synthesis
Inspirational Reading?
Forty NMR Magnets and 3000 Proteins Later. . .
Cheer Up, You Chemists
Another Chemistry Prize for Biology
RNA Interference: Film at Eleven
Nobel Update: RNAi Wins
Nobel Fever Is Upon Us
By Any Other Name
If You Want Your Explanations Overnight, It'll Cost You
Explain This, Hot Shot!
Ray Kurzweil's Future
Peptide Craziness
Pounding Sand
Aluminum: Friend or Foe?
Outside Reading
Attack of the Angry Viruses
Play by Play in the Lab
Start Your Engines
The Tiniest Doors Begin to Open
Outside Reading
For Further Enlightenment
An Off-Topic Ramble
Why Carbon Matters
Exobiochemistry
How Often Do We Land on Another World?
More Fun With DNA
Tadpoles to the Rescue?
Memorial
The Dull Edge of Nanotech
A Birthday Worth Noting
Nuclear Fusion, Wordsworth, German Cooking. The Usual.
A Request From Biology
Looking Back, Looking Forward
Place Your Bets
Unequivocal Good News
A New Form of Hype, uh, Life?
What I, um, Meant to, um, Say
Left and Right, Revisited
Y'all Are Going to Think I'm Nuts, But. . .
The Good Old Days of Really Bad Teeth, Revisited
Et in Arcadia Ego
Faces In the Clouds
Cloning's Growing Pains
Nobelity and Lesser Nobelity
Another Stuffed Shirt
Nobel Time!
The Bigger They Are
Our Friend the Phosphate Group, Redux
Our Friend the Phosphate Group
A Strange Compound, In Strange Places

Graduate School
Dealing With Dishonesty
The UCLA Lab Fatality: Criminal Charges Filed
The NIH Wonders About the Future of Biomedical Workers
Sezen / Sames: What Does it Say About Grad School?
The Fox's Lament
In Which I Reminisce About the Prins Reaction, Chemical Abstracts, and John Keats
The PhD Problem
The Hours You Put In
Posters and Pickiness
How Long Would It Take - If Everything Worked?
How Much is the PI To Blame?
Gegen die Dummheit . . .Well, Guess Who Wins, Again
Reasons Not to Go to Grad School?
I'll Get Right On That For You, Professor
Random Questions, Answered Randomly
The Real Hazards of the Lab
Out the Door and Down the Stairs
More Than This
How Not To Do It: Water Aspirators
Scrape Off Some Attitude
And It Goes Like This!
Looking Backwards
Understanding Dawns
Cheer Up
". . . Jobs That Don't Exist"
Pilferage
The Doctorate and Its Discontents
Doctorate or Not?
Fish Nor Fowl?
Decisions, Decisions
Depraved and Deprived
Levoglucosan
German, Anyone?
Tenderbutton Calls It Quits
Spectroscopic Days
If You Want Your Explanations Overnight, It'll Cost You
Hobson's Choice
Academia in Summertime
Grad School, Blogged
Arcadia's Furnishings
Never Came In Handy. Not Once.
. . .It's a Wonder I Can Think At All
Industry vs. Academia: The Mental Aspect
Differences Between Industry and Academia, Pt. 1
Sweet Maybe, But Trouble, Too
A Couple of Days Off

How Not to Do It
Storage of Industrial Chemicals, Gone Rather Wrong
How Not To Do It: Hydrogen Gas Mixtures
Max Gergel's Memoirs
How Not to Do It: Acetylene Cylinders
Phthalate: A Natural Product? Sure 'Bout That?
How Not to Do It: Liquid Oxygen Cylinders
Mental Health Break: The Alkali Metals Show Their Personalities
Manfred Christl Rides Again (Bonus Idiotic Lab Accident, Too)
How Not To Do It: The Secret Patent Decoder Ring
How Not To Do It: Water Aspirators
How Not To Do It: Diazomethane
How Not To Do It: Column Chromatography
How Not to Do It: Hydrogen Bromide
How Not to Do It: More Diethyl Ether (Now With Extra Hardware)
How Not to Do It: Tertiary Butyllithium
How Not To Do It: Ruining Stuff
How Not to Do It: Sophomore Organic Edition
How Not to Do It: Distilling HMPA
How Not to Do It: Liquid Nitrogen Tanks
How Not to Do It: Ether Peroxides
How Not to Do It: Bromine
How Not to Do It: Vacuum Pumps
How Not to Do It: Distilling Benzene
Speak for Themselves, They Do
Ping! Ping! Ping!
How Not to Do It: Sulfenyl Chlorides
How Not to Do It: Sodium
How Not to Do It - Hydrogen Balloons
Our Friend, the Carbon-Aluminum Bond
How Not to Do It: Solvent Stills
Not Like Law School

How To Get a Pharma Job
Imperfect Pitch
Walk Around Some
Making the Adjustment to Smallness
If Not This, What?
Hey, Graduates! Negotiate Hard, You Hear, Now?
". . . Jobs That Don't Exist"
More on Interview Seminars
Starting Up Again
Fish Nor Fowl?
Decisions, Decisions
Have We Got a Job For You!
Are You Experienced?
The Other Side of the Table
Bad Interviews
Man Hands on Misery to Man
Here's A Shovel. Could You Dig Yourself In Some More?
Name Reactions for One Thousand, Alex
Hire the Thoroughbreds?
What Sort of Training?
Dinner the Night Before
Getting Hired as a PhD
How To Get Hired: Associate Positions
Sneaking Out for an Interview
Getting A Job

In Silico
Putting a Number on Chemical Beauty
A Look Into the Future?
Where's the Best Place to Apply Modeling to Drug Discovery?
Foldit Notches a Protein Structure Success (And Some Failures)
Design a Molecule, Win an IPad (Which is More Than You Usually Get)
Modeling and Structure
Value in Structure?
Maybe We Should Make It More of a Game
Free Software
What Has Bioinformatics Ever Done For Us?
Modeling in Drug Discovery: Questions?
Unlovely Polyphenols
Bill Gates Put Some Money On Schrödinger
Another Proposal For the Scientific Literature
Compounds and Proteins
We Don't Know Beans About Biotin
Benford's Law, Revisited
Selective Scaffolds
Why Don't We Have More Protein-Protein Drug Molecules?
Side Effects, Predicted?
Warren DeLano
The Further In You Go, The Bigger It Gets
Why Does Screening Work At All? (Free Business Proposal Included!)
What's So Special About Ribose?
Another Thing We Don't Know
Jargon Will Save Us All
Mexican Lemons To the Rescue
The Motions of a Protein
Structure-Activity: Lather, Rinse, and Repeat
Floppiness Is Not Your Friend: Who Knew?
Protein Folding: Complexity to Make More Complexity?
X-Ray Structures: Handle With Care
Up Close and Personal
O Pioneers!
Start Small, Start Right
Smaller, Wetter, Harder to Work With
Melting Keys and Squishy Locks
No Shortcuts
Wrong, But Still Convincing
Love and Anger
Enzymes Do Whatever They Want To
Crystals of Doubt
Molecular Modeling Cage Match
The Hazards of Molecular Modeling
Clamping Down, or Loosening Up?
Crossing Your Fingers, Authoritatively
Kinases and Their Komplications
FullCell 1.0?
The March of Folly
Reality's Revenge

Infectious Diseases
The XMRV Story Is Not Getting Any Saner
Cyclodextrin's Day in the Sun
XMRV - Work Went On
XMRV: This Is Not Good
XMRV: Over With and Done?
Chronic Fatigue: Enough Energy Left for Death Threats, Anyway
Kibdelomycin, A New Antibiotic. In A Way.
DRACOs: New Antivirals Against Pretty Much Everything?
The Evolution of Resistance: Are We Doing It Wrong?
Murine Viruses and Chronic Fatigue: Does the Story Continue
XMRV and Chronic Fatigue: Down For More Than the Third Time
Process Chemistry Makes the Headlines
Selenium In a Drug Structure: Why Not?
Pfizer Moves Antibacterials to Shanghai
XMRV: It's Ugly, But That's Science
Chiral What? Chiral How?
HIV Therapies: A Thank-You
TRIM21: A Cure For the Common Cold? Maybe Not. . .
XMRV? Or Umpteen Other Viruses? Or What?
Know How to Make Praziquantel? Tell The World.
XMRV and Chronic Fatigue: You Thought You Were Confused Before
Unlovely Polyphenols
Rosetta@Home
A Landmark In Clinical Trial Data Interpretation
Dundee's NMT Inhibitors for Sleeping Sickness: An Update
Good News Versus Sleeping Sickness
Your Own Personal Bacteria
A Friday Book Recommendation
XMRV and Chronic Fatigue Syndrome: More Negative Data
A Pile of Malaria Leads For the Taking
Two Doses of Crazy
Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?
Ozonides As Drugs: What Will They Think of Next?
Chronic Fatigue - Retroviruses to Blame, or Not?
A Nobel for Ribosome Structure
A Deuterium Deal
Altermune - Real Stuff or Not?
Don't Hit The Bunkers Just Yet
An HIV Drug. Or A Gout Drug? Or Both. . .
Two! Two! Two Drugs in One!
Drugs For Bacteria: Really That Hard, Or Not?
A Quick Quiz (Re: Antibacterials)
Bacteria: Respect Must Be Paid
A Cure for the Common Cold? Don't. . .Ah, Hold Your Breath
Maribavir, Ouch
Fun With Bacteria
Another Cholesterol Medication Goes Down (Or Does It)?
Whose Guess Is Better?
Smaller, Wetter, Harder to Work With
Resistant Little Creatures
Bacterial Infection: Better Or Worse Than Cancer?
Now With Ethyl Mesylate!
Evolution In Action
Brazil Raises The Pirate Flag
A New HIV Therapy. Yawn?
Deep Breaths
Vertex, Hepatitis, and Gripping the Arms of Your Chair
Peptides as Texts
Enzymes Do Whatever They Want To
Fuzeon's Fallout
A New Route to Tamiflu?
Tamiflu: Good For Anything, Or Not?
One Darn Miracle After Another
Cash For Vaccines
The Flu Plan, Part Two: Antiviral Drugs
The Flu Plan, Part One: Vaccines
Buy! It's More Expensive Than Usual!
Well Deserved
Antivirals "Gathering Dust"?
The Check Shows Up in the Mail. Really.
And It Goes Like This
More on Brazil and Kaletra
Brazil Pulls Out the Pin
Where's the Combo?
Fan Mail
Pfizer Opens Their Wallet - Again
Fungal Problems
Dr. Rath Does What He Can
Vertex Turns Over a Winner
Do It Again
An Antiviral Example
Can Med-Chem Help With Bird Flu?
Empty Shelves
Resistance to Resistance
It's a Bacterial Planet, You Know
They Will Do Such Things. . .
A Last-Ditch Effort - Or Is It?
Better Them Than Me
A Twisty Road
New! Viruses So Potent, You'd Swear They Were Homemade!
If It Were Easy. . .
New Drugs for HIV

Inorganic Chemistry
Surfin' On The Surface
Neil Bartlett, 1932-2008
Copper: A Gentleman's Disagreement
A Salute

Intelligent Design
Unintelligent Design
Brief Political Interlude
Ban Intelligent Design?
Poor Put-Upon Intelligent Design
The Dover Decision Comes Down
Intelligent Design, Molecule By Molecule
The Dover Decision
An Off-Topic Ramble
Intelligent Chemical Design

Life As We (Don't) Know It
Arsenic Bacteria Ride Again. (Or Don't).
A First Step Toward A New Form of Life
Arsenic in DNA: The Kinetic Argument.
Life With Arsenic: Who'd Have Thought?
Chemical Biology - The Future?
Let's Sequence These Guys
Friday Book Recommendation
What's So Special About Ribose?
Mass Spec on Mars
Intelligent Chemical Design
Exobiochemistry
Our Friend the Phosphate Group
Mirror Stars

Life in the Drug Labs
Potassium Hydride Is Not Your Friend
The Future of Pharma? Yikes.
Putting a Number on Chemical Beauty
Open Office Plans - A Question or Two
This All Too Open Office
The Research World Staggers Back to Work
Uranium, Eh?
Rating A Massive Pile of Compounds
Fish Nor Fowl
Tossing Out the 1920s Hydrogenators: Can It Be Done?
Fifty Years of Med-Chem Molecules: What Are They Telling Us?
From the RSC/SCI Symposium: A Med-Chem Anomaly
Disappearing Information, Courtesy of Aldrich Chemical
Drug Research Areas You Wish You'd Never Heard Of
High Pressure - The Good Kind
Chem-Geekery: Name Reactions You've Never Run
Underused Lab Solvents
Pfizer's Brave New Med-Chem World
What Would You Get Rid Of?
A Complete Diversion: Purple Compounds
What Medicinal Chemists Really Make
Return of the Magic Methyl Group
In Which I Reminisce About the Prins Reaction, Chemical Abstracts, and John Keats
Surely You Have Something Else to Do
A 200-Proof Shot of Medicinal Chemistry
Brave New Office
It's Worth It to Know That There Are Others
Dogs and Ponys
Fluorination Without Tears. Or Panicked Shouts.
A Quick Glassware Question
Novartis and the Labs of the Future
Comment of the Day: Outsourcing and Architecture
Good Old Medicinal Chemistry: What Can You Get Away With?
Shine A Light
Enthalpy and Entropy Again
Settle A Bet
If You're Not Excited, Sit Down
Keeping Track Of All Those Chemicals
Palladium Couplings: You Can't Run Them All
Conference Thoughts
Workhorse Reactions
Put In Another Methyl Group: A Villanelle
Six Sigma in Drug Discovery? Part One - Are Chemists Too Individual?
Intermediates
How Much Compound?
Nanopowders?
Sparteine and Other Fine Chemical Shortages
A Quick And Nerdy Question
Curse of the Plastic Tubes
Compounds and Proteins
Privileged Scaffolds? How About Unprivileged Ones?
The Chemical Suppliers: Customer Reviews
Good Suppliers - And The Other Guys
Science Buildings: Good, Bad, and Weird
Not Gonna Make That One
Flowing, Not So Gently
Cranking Away
Chemical Supplier Question
The Infinitely Active Impurity
In Hoc Signo Non Vinces
What Should Non-Chemists Know About Medicinal Chemistry, Anyway?
Oxford's New Building, One Year Later
Data, Raw and Otherwise
Recommended Books For Medicinal Chemists, Part One
Fear Of Academic Chemistry?
But These Reagents, Where Are They?
What Are the Best Med-Chem Books?
Lumpy Assay Results
Lab Equipment: Any H-Cube Troubleshooters Out There?
Four Med-Chem Questions
Reduce Your Number of Reductions, Why Don't You?
Elements I Have Yet to Use
Consultants
Hoist, Petard, Etc.
Retire These Reactions!
Colorful Junk
Sulfoxides: A Sneaking Affection
How A Real Drug Industry Project Meeting Goes
Everything In Its Place
RUR
Funky Carbocycles
Ugliness Defined
Don't Make Them in the First Place?
Random Questions, Answered Randomly
Instant Med-Chem Wisdom
Ever Have One of Those Days?
Wait For It. . .Wait For It. . .
Surfin' On The Surface
The Mechanical Chemist?
The Equipment Graveyard
Your Temperamental Diva Reactions
How Good (or Bad?) Are Patent Procedures, Anyway?
Hot Chemistry, Low Tech to High
Inspiration Is Where You Find It
Structure-Activity: Lather, Rinse, and Repeat
The Limits of Free Scientist Chow?
Supplies of Suppliers
Prep TLC: The Good Old Days Live On
Fancy Building, Fancy Science?
The Real Hazards of the Lab
Lack of Experience, You Know
Poor Equipment Revisited
The Perils of Poor Equipment
The Yield Monster - And Its Friend, The Model Monster
We Now Return to Our Regularly Scheduled Program
Out the Door and Down the Stairs
Fearful Symmetry?
Old School - Really Old
Why Don't You Just. . .
Sugars: Still Crazy After All These Years
How Not To Do It: Water Aspirators
Fighting Boredom, Profitably
Questions You Don't Necessarily Want the Answers To . . .
Backtracking, Necessary and Unnecessary
Lowe's Law of Diurnal Distribution
How's The New Boss Doing?
I Can Has Ugly Molecules?
Tote That Barge, Lift That Bale
Oops
Ah, Glassware
The Miracle Solvent
Copper: A Gentleman's Disagreement
Summer Student Time
Explaining It All
Naming of Names
Walk Around Some
A Meditation on Solvents
Another Pop Quiz!
The Lucky Bonus Pack
Putting Out the Inevitable Fires
One Time Only. Or Maybe Just a Few.
Write It Down, Write it Down
Dig the New Breed
A Few Questions For My Fellow Pharma Chemists
Extractions: A Way of Life
Cheap Happiness
Winterize Your Ideas
Scrape Off Some Attitude
Underperforming Triple Bonds
The Big and the Little
Still and All
You Do The Easy Stuff; I'll Do the Easier
Maybe Not Improved, But Definitely New
How You Doin'? How's Everybody Doin'?
Here Be Chiral Dragons, With Fluorinated Fangs
Looking Backwards
No Problem At All
Go With The Er, Flow?
Don't Step Over It, Even If It's Right in Front of You
Fresh Air, Or What Passes For It
Aromatherapy
Here It Goes
These You Shall Have Always With You
Run! Anthropologists!
A Farewell to Tin
Over There, Behind That Stack of Whatchamacallits
Starting Up Again
Sunbeams, Single Electrons, and You
Safer Every Day!
Forewarned is Forearmed
The Doctorate and Its Discontents
Doctorate or Not?
Sulfur, Your Pal. Mostly.
I Want A New Nitro
Lousy Reactions: Reader's Choice
Something From Nothing
Wake Up and Smell the Solvents
Problems and Solutions
Good Stuff and Bad Stuff
You'll Be Safe Under Here. Maybe.
Cleans Down to What Should Be the Shine
Old School? Same School!
Family Portraits
Five Things I Haven't Used in Years
Test Your Skills!
By Any Other Name
The Last Word on Eerie Glowing Labs
The Future is Unwritten
More Purple Radiance
Memo to the Public Relations Department
Best When Used By. . .
A Day at the Rota-Vap
Sulfurous Stenches: A Connisseur's Guide
The Process of Process
Cleaning Out the Hood: An Internal Monologue
Grad School, Blogged
First Slide, Please
Stream of Consciousness
The Good New Days
Gimme That Old Time Reaction
Sort Of Like A Wine Cellar
Home Sweet Home
. . .And That Settles It
Gooooaaaal!
The Latest in Pharmaceutical Technology
Tribes
A Sensitive Guy
Having the Hands
Differences Between Academia and Industry, Pt. 4
Let's Check This Blank Page, Here
Seven Questions
Hydrogenation Made Easy?
How Safe Is This Stuff?
The Voice of Experience
Cuprate Voodoo
Sneaking Out for an Interview
A Smelly Riddle
Lost Arts
Ten Questions
Ancient Metals
The Latest from the Fume Hood
Law and Disorder
Does Your Labmate Have the Hands?
Glassware Geek
Through the Looking Plastic
Our Friend the Nitrogen Atom
Lab of the Future!
Beg to Differ
Chemistry Geekery
Nine Things I'm Having Trouble Imagining
A Visit To Academia
Well, Sonny, That's Not How We Did It
It's All Local, All Right
A Spin of the Wheel
Ping! Ping! Ping!
A Day in the Life: Dichloromethane and Peanut Butter
Public Utility, You Say?
We Have Ways of Keeping You Safe
Measure for Mismeasure
Rational Drug Design
A Week in the Life
Solid Citizens
Lighting Out for the Frontier
Wipe Down
The Latest From the Fishing Hole
Catalyst Catfishing
Next on the Food Channel. . .
The Last Word on Taste
Beyond the Teeth, Beyond the Pale
By Any Other Name
At My Desk, Playing 500-Card Stud
Mutter, Mutter, Mutter
Obvious to One Skilled in the Art
Quis custodiet ipsos custodes?
A Quick One While He's Away
A Chemical Wish List
Multitasking
Idle Hands
And I Still Have Some of Those Shirts
Talk, Cheap and Otherwise
More Pfizer Explosion Details
Blowups Happen
Another Shot
A Clean Lab is A Happy Lab
Back to Whatever It Is I Do
Colors May Fade
More Colors and Smells

Lowe's Laws of the Lab
Prediction Markets, Idea Sharing, and So On
Cheese Dip and Hydrochloric Acid
A Law of the Lab: Yields and Variations
Yet Another Law
Another Law of the Lab
Think Twice
Law Number One

Metaphors, Good and Bad
Block That Metaphor!
Melting Keys and Squishy Locks

Natural Products
Kibdelomycin, A New Antibiotic. In A Way.
Chiral What? Chiral How?
And One Was Just Right?
Vinca Alkaloids, And Where They End Up

Odd Elements in Drugs
Selenium In a Drug Structure: Why Not?
You Don't See Many Names Starting with "Tellura-"
Ozonides As Drugs: What Will They Think of Next?
One For the Brave
Arsenic, Patents, and the World
My Shopping List
Odd Elements in Drugs: Silicon
Odd Elements in Drugs

Patents and IP
Academia and Industry, Suing Each Other
Don't Dose That Patient Until You Pay Up
Amgen's New Patent: Explanations, Anyone?
A New Book on Chemical Patents
Patent Trolling, Money and Fun
A Dish Best Served Cold
Chinese Research: Not Quite the Juggernaut?
Roche Prevails Over Stanford
Roche and Stanford: Academia v. Industry?
Freedom to Operate
Are Genes Patentable Or Not?
Apotex's Plavix Adventure: Four Years Later
You May Not Be Interested In It - But It's Interested In You
Running Out of Decent Molecules to Patent?
Patent Chart Update
Take These?
Only Three Patents? Really?
The Ariad Decision and Written Description
Myriad's BRCA Gene Case: Wait For It
Ariad Loses on Appeal
Drug Patents in India
Acorda and Ampyra
So, Do I Own This, Or What? Answer: What
In Which You Get to Hear the Phrase "Hatch-Waxman" Again
How To Get Useful Data Out of a Drug Patent
Ignoring Patents?
Thalidomide for Myeloma: Whose Idea Was It?
Ariad's Patent Rises From the Grave to Smite the Living
Polymorphs and Salts: India Raises an Eyebrow
How Not To Do It: The Secret Patent Decoder Ring
Professors Patent Pathways and Possibly Profit? Please.
Perpetual Patents: A Nasty Thought Occurs
Perpetual Patent Motion Machine
Deuterated Drugs: The PTO Says OK, So Far
Ariad's Patent: Let Us Now Dance In Circles
How Good (or Bad?) Are Patent Procedures, Anyway?
Ariad's Patent: A Court Rules
Rember for Alzheimer's: Methylene Blue's Comeback
Confident
Patents Stopping an Alzheimer's Wonder Drug?
Unknown - But You Can Buy It
Hearing Footsteps
Fixing the Patent System?
Ugly, But Useful
Arsenic, Patents, and the World
Nonsense. On Stilts. Playing a Trumpet.
Brazil Raises The Pirate Flag
Obvious Ain't Obvious No More
Crichton, Patents, and Genes
The Paper Mountain
Show What You Know
Inherently Obvious - It's Obviously Inherent
Move On, Move On - Nothing To See Here. . .
Ariad's Patent Eviscerated
Plavix Plot Twists
Respect! Honor! Recognition! All For $149.95!
The Great Plavix Disaster
Getting and Spending
Ariad Wins a Round
Full Disclosure
A Shot Across the Bow
Ariad's Day in Court
Once More Into the Patent Breech
Down With Patents, Eh?
Ah, It's Fine. Just Send the Darn Thing Out Already.
The Examiner Finally Snaps
Arr, Me Hearties!
The Leash of the Law
Brazil Pulls Out the Pin
Vaccines and Human Folly
The Research Exemption Lives!
Merck and Integra Go the Distance
Between Friends. Sort of.
Back For More
Dysfunctional Disclosure
Elbow Room
Merck Takes Another One
Success Has A Thousand Fathers
Fixing the Drug Industry?
Keep It To Yourself
I'll Have the Lot
Alexander Would Have Understood
Hey, I Could Patent That. . .
Will the Uncommon Work for the Common Good?
Living by the IP Sword
Back for More
Lighting Out for the Frontier
Doublets, Triplets, Whateverlets
This Isn't the Kind of Office Action You're Thinking Of
All the Myriad Ways
Owning the Road
Why Own the Car, When You Can Own the Road?
Oblivious to One Skilled in the Art
Obvious to One Skilled in the Art
How to Be an Inventor
From Each According To Their Creativity, To Each According To Their Difficulty?
And Now for Something Completely Different